latest research on herpes cure

BioNTech doses first patient in herpes vaccine candidate clinical trial

Keep up with the latest medical breakthroughs and healthcare trends with the Reuters Health Rounds newsletter. Sign up here.

Reporting by Tristan Chabba in Gdansk Editing by Miranda Murray

Our Standards: The Thomson Reuters Trust Principles. , opens new tab

Xiaomi takes aim at Tesla in Chinese auto market with $29,870 electric car

Chinese smartphone maker Xiaomi launched a sporty electric car on Thursday with styling cues drawn from Porsche and priced below Tesla's Model 3, highlighting the stiff competition from new entrants in an already crowded EV market in China.

An official website of the United States government

The .gov means it’s official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

• Publications
• Account settings

Preview improvements coming to the PMC website in October 2024. Learn More or Try it out now .

• Advanced Search
• Journal List
• Vaccines (Basel)

Insights into the Novel Therapeutics and Vaccines against Herpes Simplex Virus

Shiza malik.

1 Bridging Health Foundation, Rawalpindi 46000, Pakistan

2 Department of Microbiology, Institute of Medicine, Tribhuvan University Teaching Hospital, Kathmandu 44600, Nepal

3 Department of Microbiology, Dr. D. Y. Patil Medical College, Hospital and Research Center, Dr. D. Y. Patil Vidyapeeth, Pune 411018, Maharashtra, India

4 Department of Medicine, School of Health Sciences, Foundation University Islamabad, DHA Phase I, Islamabad 44000, Pakistan

Khalid Muhammad

5 Department of Biology, College of Science, UAE University, Al Ain 15551, United Arab Emirates

Yasir Waheed

6 Office of Research, Innovation, and Commercialization (ORIC), Shaheed Zulfiqar Ali Bhutto Medical University, Islamabad 44000, Pakistan

7 Gilbert and Rose-Marie Chagoury School of Medicine, Lebanese American University, Byblos 1401, Lebanon

Associated Data

Not applicable.

Herpes simplex virus (HSV) is a great concern of the global health community due to its linked infection of inconspicuous nature and resultant serious medical consequences. Seropositive patients may develop ocular disease or genital herpes as characteristic infectious outcomes. Moreover, the infectious nature of HSV is so complex that the available therapeutic options have been modified in certain ways to cure it. However, no permanent and highly effective cure has been discovered. This review generates insights into the available prophylactic and therapeutic interventions against HSV. A methodological research approach is used for study design and data complication. Only the latest data from publications are acquired to shed light on updated therapeutic approaches. These studies indicate that the current antiviral therapeutics can suppress the symptoms and control viral transmission up to a certain level, but cannot eradicate the natural HSV infection and latency outcomes. Most trials that have entered the clinical phase are made part of this review to understand what is new within the field. Some vaccination approaches are also discussed. Moreover, some novel therapeutic options that are currently in research annals are given due consideration for future development. The data can enable the scientific community to direct their efforts to fill the gaps that remain unfilled in terms of therapies for HSV. The need is to integrate scientific efforts to produce a proper cure against HSV to control the virus spread, resistance, and mutation in future disease management.

1. Introduction

Herpes simplex virus (HSV) belongs to the family of Alphaherpesvirinae with a characteristic double-stranded DNA structural composition [ 1 ]. Its two main serotypes, HSV-1 and HSV-2, are mainly known for their links with infectious diseases [ 2 ]. According to estimates by WHO, approximately 70–90% of the population worldwide is seropositive for HSV-2, which makes it a great concern for the healthcare community regarding the possibility of developing infections (James & Kimberlin, 2015b) [ 3 ]. HSV-1 is considered the main causative agent of ocular infection that may occur in patients already having diseases such as genital lesions, keratitis or retinal necrosis, encephalitis, iridocyclitis, or conjunctivitis [ 4 , 5 , 6 ]. Some studies have also established links between longstanding HSV-1 serology with psychological complications, including Alzheimer’s disease [ 7 ]. On the other hand, HSV-2 is predominantly linked with characteristic genital herpes disease of the herpes virus. These infections are worldwide, irrespective of the developing or industrialized national standing [ 8 ].

HSV-2 virus is a sexually transmitted infectious agent that is prevalent in approximately 536 million people worldwide, standing at an annual incidence rate of about 23.6 million cases, as per the updates by the CDC [ 9 , 10 ]. The genital area is the prime target of viral infection; however, it may also cause infections similar to HSV-1, including necrotizing stromal keratitis in the eyes, meningitis, encephalitis, and neurological complications [ 11 ]. However, not all HSV-2-positive cases develop genital herpes or ulcerative and vesicular lesions because the virus mostly remains in a latency phase that makes it possible to transmit to other members of the populace without getting noticed and without exhibiting any infectious outcomes [ 12 ]. In simple words, the sexual transmission may not be coupled with a clinical history or symptomatology of genital herpes. The symptomology makes the viral presence rarely fatal, but the same is not the case for babies from infected mothers and pregnant ladies, due to their immunocompromised system and susceptibility to easily acquire infection [ 12 , 13 , 14 ].

The most prevalent feature that makes HSV infection complications is its ability to enter a nonreplicating latency period, which enables it to survive long periods of inactivation within the host and gives it the ability to reactivate and infect the host under different external and internal stimuli [ 12 , 13 ]. The latency period is mostly asymptomatic; thus, viral transmission during this period remains unrecognized. This aspect is considered the major reason for the large-scale seroprevalence of HSV [ 13 ]. Additionally, it can infect almost every type of cell for the characteristic receptor recognition strategies, making it pertinent to large-scale population spread [ 10 ]. This property is associated with the presence of hundreds of diverse glycoproteins in HSV lipid bilayers that alter its receptor recognition and viral entry into host cells [ 8 , 15 , 16 , 17 , 18 , 19 ]. Furthermore, it uses multiple strategies for viral fusion, endocytosis, and transmission among cells, all of which cause further complications its treatment procedures [ 20 , 21 ]. Thus, most of the therapeutic studies are limited in terms of their effectiveness and inability to eradicate infections.

The complex nature of the virus, in terms of symptomatic infections and asymptomatic presence and recurrence, makes its cure difficult; for this reason, no vaccination or therapeutic cure has been devised that could completely eradicate HSV infection [ 21 , 22 ]. Moreover, the lifelong presence of HSV-2 infection further complicates the treatment procedures because it may require prolonged administration of standard proposed treatments, which is in line with its resistive nature [ 12 , 23 ]. In this review, we discuss the primary nature of HSV that makes it complicated for the design of therapeutics. This understanding can set the pace for further insight into the therapeutic interventions designed to date [ 24 ]. We discuss how the antiviral strategies are designed knowing the complexities associated with viral entry, infection, and persistence. The focus is on therapeutic developments that may hold hope for future control over HSV infections.

2. Materials and Methods

A systematic approach was used to gather the latest data regarding the different dimensions of H. simplex virus infection and the accumulated therapeutic and vaccination strategies. We searched electronic sources such as Google Scholar, Pub Med, NIH (National Library of Medicine), Scopus (Elsevier), and Web of Science. Moreover, the official websites of WHO, CDC, UNAID, and FDA were also used to obtain the statistical results and latest updates regarding HSV epidemiology, as well as ongoing treatment efforts. As the studies mainly incorporated the data regarding therapeutics against HSV viruses, the major research terms were “Herpes simplex virus”, “HSV infection”, “therapeutics against HSV”, “antiviral agents”, “vaccines against HSV”, “therapies against HSV”, “novel therapeutic approaches”, and some other linked search terms. After a thorough analysis of the dates, abstracts, titles, and journals of research publications, they were made part of this review. The process of information gathering was not limited to a few studies but rather collected from research compilations in the form of original research articles, reviews, short commentaries, case reports, and letters to the editors. Lastly, the search strategy was limited to incorporating data from 2010 to 2022 to add only the most recent advances related to HSV disease management.

3. Results and Discussion

3.1. the pathological biology of hsv and associated infection.

As explained earlier, HSV belongs to the family of neurotropic alpha herpesviruses, which are well known for latency features [ 4 , 12 ]. The virus particle consists of an internal dense electron core that contains the reproductive material in the form of double-stranded DNA [ 25 ]. All age groups of people are prone to developing HSV infection. Some other pathogenic species of viruses belonging to the same DNA herpes family of viruses include varicella-zoster virus (VZV), Epstein–Barr virus (EBV), cytomegalovirus, and human herpes types 6, 7, and 8 [ 26 ]. The two subtypes of HSV-1 and HSV-2 share close genomic relevance with >80% of the amino-acid identity profile. Moreover, both share the common infectious nature of causing oral and genital ulcerations [ 26 , 27 ].

HSV DNA has been well studied and formulated to encode 70+ genes. The genomic portion is enveloped by a viral capsid of icosahedral shape that in turn displays >162 known protein units (capsomers) [ 28 , 29 ]. The virus capsid is further surrounded by a lipid bilayer envelope consisting of tegument proteins and several dozen glycoproteins on the surface. Of this GP, five glycoproteins with known functions are gB, gC, gD, gH, and gl [ 30 ]. These proteins facilitate host viral coordination in terms of attachment, binding, and host cell penetration and entry [ 31 , 32 ]. The complex mechanism of HSV host interaction and its latency period present scientists with a great challenge [ 33 ]. The host virus entry mechanisms, cellular interaction, and infectious cycles are, thus, the prime focus of understanding for scientists developing therapeutics. This is discussed in relevance to HSV therapeutics in a later section of this article to describe to the readers the procedures, limitations, and progress achieved in this domain [ 27 , 34 ].

The virus Infection mainly begins with the epithelial cells of the skin or mucosal surfaces. The virus particle then trickles down to nerve endings and nerve axons, where the virus undergoes persistent infection within the trigeminal or lumbosacral ganglia region [ 12 , 35 ]. After establishing virus progeny in this area, it returns to the mucosal and skin surfaces to produce oral or genital ulcers. At other times, it remains asymptomatic, associated with viral shedding and silent transmission to other hosts [ 36 , 37 ]. This asymptomatic and silent transmission nature makes HSV spread quite extensively unnoticed in the population, as most cases remain subclinical and, thus, hidden from diagnosis [ 1 , 21 ]. The clinical manifestations of HSV-1 and HSV-2 vary depending on the age group, entry route, host immune response, and initial or recurrent nature of the infection [ 1 ].

HSV-1 is linked with episodes of genital and neonatal herpes, in addition to mainly causing oral and facial infections [ 38 ]. The disease incidences are higher in HICs, though the disease occurrence rates in neonates are lower compared to the incidence in children in LICs, where ≥90% people acquire HSV-1 infection by adolescence, which makes it a great healthcare burden for the world [ 10 ]. The major disease outcomes of HSV-1 infection include herpes labialis, gingivostomatitis, HSV-linked infectious encephalitis, keratitis, and pharyngitis [ 39 ]

HSV-2, on the other hand, is mainly dependent on sexual transmission and is associated with genital ulceration (genital ulcer disease (GUD)). Apart from the risk of neonatal herpes and possibly being associated with the development of neurological disorders such as Alzheimer’s at a later age, an increased risk of developing HIV infection is linked to HSV-2 infection [ 1 , 12 , 14 ]. The disease incidence is continuously rising on an annual basis due to the silent nature among sexual partners with high HSV-2 seroprevalence [ 3 , 13 ]. Additionally, the incidence rates are mostly outlined for high-income countries where R&D is progressively outlined in databases, while, in the case of low-income countries, the incidence rates are still unknown [ 10 ]. Neonatal herpes infections are often the major causes of increased morbidity and mortality rates. Most importantly, HSV-2 infection and transmission are linked with up to threefold increased incidence of HIV epidemics, with incidence rates up to 23–50% being the major concern regarding healthcare management. Moreover, the clinical complications in terms of life-threatening incidences may be accounted for in immunocompromised individuals [ 40 ].

The major diagnostic tests performed for HSV detection mainly include polymerase chain reaction, type-specific serological essays, viral culture, and antigen detection assays, which differentiate between the two subtypes of HSV [ 21 , 41 ]. The main treatment strategies against genital herpes mainly include antiviral treatments, such as acyclovir, valacyclovir, or famciclovir among other antiviral agents mentioned by WHO guidelines [ 3 , 9 , 22 ]. Most of these treatment regimens require continuous application to reduce the symptoms without permanently dealing with the virus prevalence. In the upcoming sections, we discuss the various therapeutic strategies and vaccination efforts against HSV carried out recently, as well as outline the futuristic perspective for HSV treatment.

3.2. Current Vaccination Efforts against HSV

Currently, no vaccine has been specified against HSV infection; however, several vaccination candidates are in research annals for vaccine development. Most of the clinical efforts are directed toward HSV-2 for its greater infectious outcomes, but HSV-2 vaccines will have benefits against both subtypes of viruses because of their sequence homology [ 42 , 43 , 44 ]. Several lines of research show that HSV vaccination is feasible. Successful vaccination strategies against varicella-zoster virus by using replated herpes virus biology, bovine herpesvirus-1, and herpesvirus-1 (pseudorabies virus) indicate that effective vaccine efforts against HSV can be successful [ 44 ]. Similarly, work on vaccines along with antiviral adjuvants has also presented preventive abilities against herpes zoster infection, with proven 97% efficacy in phase III trials [ 43 , 44 , 45 ].

Studies on human papillomavirus vaccination protocols are also helping with the understanding of immunomodulatory regulation which can be effectively induced with vaccination against HSV [ 43 , 46 ]. Some other research groups tested herpes vaccine trials with truncated glycoprotein D2 (Gd2T) vaccines tested on thousands of HSV-positive cases and demonstrated vaccine efficacy of up to 58% against HSV-1 with little or no effect against HSV-2. These studies indicated that immunomodulation against HSV-1 can be achieved with antibody titers, but the same cannot yet be shown for HSV-2 [ 21 , 30 ]. Additionally, the viral sequencing, widescale data availability, and genetic profiling for both HSV-1 and HSV-2 predict that better vaccination protocols could be implemented with the identification of potential targets for therapeutic development. With proper and coordinated efforts among bioinformaticians and clinicians, these efforts could be successful [ 46 , 47 ].

The rigorous efforts put forward for vaccination development come in two major forms, preventive and therapeutic vaccination protocols [ 48 ]. The former provides pre-exposure immune-protective responses against HSV-2 infection development tested over the long term up to phase III trials [ 43 ]. These trials have mostly been limited to HIC. It is hypothesized that the same preventive vaccination practices in LMIC could produce better results in terms of disease mitigation and adaptive management. For this cause, the geographic strain diversity must be accounted for during vaccination development to ensure the nonrestrictive geographic nature of HSV vaccination. Scientists propose that, if any candidate vaccine was found to be effective for both HSV subtypes, it could be shifted from adolescents to infants for the possible prevention option [ 14 , 49 ].

Therapeutic vaccines, in contrast, are being tested to reduce the disease symptoms and viral transmission across the hosts, for the larger benefit of public health management. For this route, the targeted populace is mostly HSV-2-infected persons. Some therapeutic candidates have been checked up to phase I and II trials with proven antiviral effects, as well as decreased viral shedding and lesion formation in infected subjects [ 30 , 48 ]. Similar to the first line of preventive vaccinations, this route has also been tested mostly in HIC without solid testing in LMICs [ 20 ]; a limitation to these preclinical trials on animals is that they cannot be assumed to be effective in humans since the host viral interaction could be different in people. Thus, certain limitations are attached to phase I and II trials. Therefore, some effort should be put into clinical experimentation for rapid disease management in the future [ 47 ].

3.3. Outlining the Current Vaccines against HSV

Various vaccine candidates are in research annals for preclinical and clinical evaluation. Currently, there is no specific FDA-approved vaccine against HSV infection [ 9 ]. The ongoing clinical and preclinical trials are based on the rational understanding of HSV biology and immunopathogenesis in host cells. Some of the latest vaccine designs, their working mechanism, and ongoing trials are outlined briefly in the Table 1 .

An update on current vaccine candidates against HSV.

3.3.1. Subunit Vaccines against HSV

Subunit vaccines are composed of viral components, such as glycoproteins and protein subunits, which undergo protective immune responses to the host [ 50 ]. They have proven safer, stable, and effective for HPV vaccination design and immunization design, but still lack clinical experimental success against HSV [ 51 ]. They mostly use viral glycoproteins and antigenic mediators such as Gb/Gd/gE in their antiviral design. This type of vaccine varies in function and procures the inhibition of viral entry, viral shedding, transmission across cells, and immune-evasive responses [ 42 , 50 , 51 ]. Novel experiments are ongoing that link multiple herpes antigens and peptide epitopes in one vaccination protocol. Approximately 80–300 open readings frames (ORFs) identified by multi-omics technologies are under consideration for antigenic breadth generation and efficiency in subunit vaccines against HSV [ 42 , 52 , 53 ].

This method of vaccination provides a gateway to present complex antigenic composition to the immune system that may include T- and B-cell epitopes [ 22 , 72 ]. For testing the efficacy of these vaccines, several recombinant protein formats have been tested that are conceptually similar and undergo the introduction of HSV ORFs (complete or near complete), into bacterial or other vector systems [ 54 , 73 ]. Moreover, these vaccine combinations with certain adjuvants and vaccine formats have opened a new route to explore options for HSV vaccination in the future.

3.3.2. Vectored/DNA/RNA Vaccines against HSV

DNA- and mRNA-based vaccines have been in research annals for a long time now. The same approach has been successfully used in COVID vaccination design and is now being successfully utilized against HSV [ 74 , 75 ]. Experiments have been conducted on animal models to check the efficacy of nucleoside-modified mRNA-based vaccines against HSV-2 infection [ 75 ]. The results indicated a therapeutic reduction in symptoms within animal models in a dose-dependent manner. Moreover, these vaccines stimulate immune responses in the form of neutralizing antibodies [ 76 ]. Studies have shown that DNA is a better candidate for its stability, synthesis characteristics, and purification protocol and can be better managed compared to mRNA [ 29 , 62 ].

DNA-based vector vaccines have shown efficacy even better than subunit vaccines but not as effective as live-attenuated vaccines [ 29 , 62 ]. Moreover, some clinical concerns in the form of side-effects remain linked to the application of vehicle vector carriers [ 77 ]. Thus, adenovirus vector-based vaccines exhibit a better stability profile than mRNA vaccines. Recent studies showed the use of Vaccinia and MVA vectors for the deployment of transgenetic expression and virulence in tested subjects against different viral diseases caused by HIV, influenza, measles, flavivirus, and malaria vectors [ 11 , 45 ]. Thus, these insights into vaccination approaches compel scientists to drain effective vaccination efforts against HSV [ 78 ].

3.3.3. Live-Attenuated Vaccines against HSV

The live-attenuated vaccination method has been the most used and effective method against viral infections through history, such as smallpox vaccination, poliomyelitis, measles, mumps, rubella virus, rotavirus, and many other infections [ 63 ]. The mechanism of inactivation often includes chemical or radiation-based inactivation of virus particles. One of the antiviral vaccine candidates derived for chicken pox virus/HSV-3 (varicella-zoster virus (VZV)) is also based on a live-attenuated virus vaccination protocol [ 62 ]. It is safe and well tolerated with a highly effective profile that controls viral reactivation. This and several other examples guide a more effective vaccination protocol to be designed on the basis of this mechanism [ 43 , 62 , 63 , 64 ].

Live-attenuated vaccination has also contributed to the development of FDA-approved oncolytic virotherapy against herpes simplex virus known as (TVEC or Imlygic), which limits virus replication and regulates human immunity, and which is used for treating human melanoma [ 63 ]. Following this approach, novel vaccination drives are being tailored in medical science to reduce the side-effects and induce long-term immunity against HSV infection, with the aim of achieving prophylactic and therapeutic goals to reduce viral infection and reduce the disease symptomology [ 43 , 62 ]. Moreover, efforts are being directed to reducing the neurotropism and latency associated with HSV while designing the live-attenuated vaccination regimens. Thus, by introducing certain insertions and/or or deletions in the viral progeny, the vaccination attempts show disrupting neuronal retrograde transport and the respective inability of HSV to affect neuronal cells [ 32 , 38 , 65 ]. Some important clinical ongoing trials in this regard are provided in Table 1 .

3.3.4. Peptide Vaccines against HSV

Peptide vaccines are developed on the principle that a single molecular entity or peptide epitope could generate massive immune responses to protect against a particular disease. In this regard, immunization with immuno-dominant T-cell epitopes or neutralizing epitopes has been tested and found to be protective [ 58 ]. This system of vaccination has shown better outcomes upon the combined application of certain adjuvants such as heat-shock proteins that may be expressed in recombinant viruses or bacterial expression systems [ 37 ]. However, the complications and limitations associated with the widespread human population and differential immune responses that may entail immunodominant responses by a certain peptide hinder the development of peptide-based vaccines [ 25 , 31 ]. However, efforts are still in research annals to develop better vaccination options for both serotypes of HSV.

3.3.5. Killed-Virus Vaccines against HSV

Similar to the live-attenuated mechanism, this mechanism involves variations in terms of killed virus vaccination to avoid the risk of reactivation of viruses in subjects. Traditionally, phenol chemicals and UV light treatments have been used for this purpose, but other methods of viral inactivation have also been used more recently [ 79 , 80 ]. This approach is used as immunotherapy but remains underrated as it only provides little help to regress the viral infection, which is a property of natural infection. Recent advances have been made, and some newer studies are in progress that use sonication, chemicals, radiation, UV light, formaldehyde treatment, or their combination to cause viral death [ 80 , 81 , 82 ]. Moreover, experiments are performed by regulating the dosage amount, time, route, and number of administrations and combination with adjuvants to check the efficacy. However, further work is necessary to deduce the efficiency of this vaccination method [ 80 , 83 ].

3.3.6. Fractionated-Virus Vaccines against HSV

In these protocols, HSV vaccines are prepared by subjecting the infected cultured cells to various procedures, which inactivate the virus particles while partially purifying some viral protein subsets [ 82 , 84 ]. Trials are ongoing on such vaccination methods. In simple terms, viral characteristic proteins such as those used in peptide vaccines (e.g., gPs) are mixed with inactive virus particles and with some adjuvants to produce a binding effect of the vaccine. Previous studies have shown little or no effect on immune responses; thus, this approach requires further work to induce productive clinical outcomes [ 30 , 31 ].

3.3.7. Discontinuously Replicating Virus Vaccines against HSVs

In this method, some important genes required for viral replication or transmission are either deleted or replaced with other genes. The method is mainly used to study the functionalities of different proteins; however, the same approach is often used for designing vaccines [ 22 , 73 ]. These viruses may undergo replication but are unable to further infect the cell because they are transmission noncompetent. Because of this effect, they are termed as discontinuously replicating viruses. They exhibit the property of inability to restimulate periodically to have a recurrent, peripheral lytic replication cycle [ 47 , 64 ]. They have been checked in animal subjects for creating strong immune responses, with some candidates entering clinical trials, as indicated in Table 1 . However, further work is required for effective clinical improvement in vaccination implications.

3.3.8. Replication-Competent Live-Virus Vaccines against HSV

As the name indicates, these vaccines exhibit the replication property of viruses but undergo certain insertions and or deletion of encoded genes for application. They generate broad-scale immunostimulatory effects, including reactions from T and B cells and neutralizing antibodies. [ 85 ] They undergo the presentation of a complex mixture of epitopes with only a few missing genes. In the case of latency and reactivation from virus progeny, an endogenous re-boosting effect is created [ 12 ]. However, the limitation is that the possibility of mutation and reactivity with the wildtype strain of HSV in an immunocompromised individual may alter the vaccine mechanism. Moreover, complications may also be faced in terms of viral strain production and serological testing of HSV infection [ 12 , 13 ]. Several genetic studies have been conducted to understand which genes can be deleted for the preparation of replication-competent vaccines. This method is similar or identical to the method used in live-attenuated vaccination [ 61 , 63 ].

3.4. Therapeutics and Antiviral Strategies against HSV

When HSV infection was initially identified as a health concern, several therapeutic trials were put into research trials for evaluating different drugs against it. So much research was conducted around the time of the discovery of acyclovir back in the 1980s [ 21 ]. The search has not stopped even now, and new therapeutics are being developed that focus on different mechanisms of antiviral action [ 86 , 87 , 88 ]. This may include various approaches such as virus entry inhibitors, fusion, or virus-release inhibitors. Among these trials, N-docosanol (an entry inhibitor) is the only FDA-approved drug that is used to counter herpes labialis but not recurrent genital herpes or ocular infection [ 48 ]. More effective therapies are required to contain the global burden associated with HSV infections. Some of the major drugs with varying mechanisms of action are briefly described in the next section and a summary has been presented in form of Table 2 at the end of this section.

3.4.1. Receptor Targeting Therapeutics against HSV

These therapeutics work by preventing the receptor virus binding phenomena by targeting HSV entry molecules/receptors or glycoproteins on the host cell surface. They demonstrate both prophylactic and therapeutic efficiencies against HSV [ 38 , 47 , 89 ].

Anti-Heparan Sulfate Peptides

Two important receptor peptides, G1 and G2, have a role in binding to the cell surface receptors of HS (present in almost all cell types) and targeting them to block HSV-1 infection [ 55 ]. This phenomenon has been dose-dependently checked in cell line-based experiments. These results indicate the potential benefit of the inhibition of viral replication and cell-to-cell viral spread [ 56 ]. Similarly, experiments on animal models exhibited their prophylactic properties against ocular and genital infections. The overall number of genital lesions was reduced in tested subjects. However, a limitation of these drugs is the presence of HS receptors on all cells; thus, the drugs may produce side-effects in healthy cells, while there is a need to prevent the associated cytotoxicity [ 11 , 55 , 56 ].

Apolipoprotein E

Apolipoprotein E (apoE) is a glycoprotein that helps in viral attachment and entry by binding directly to heparin sulfate proteoglycans in the extracellular matrix of the host cell membrane [ 90 ]. Specifically, the tandem repeat dimer peptide, apoEdp, exhibits antiviral activity against both HSV 1 and HSV 2, as well as HIV. The effective results of these drugs have been shown to induce corneal infection along with immunomodulation in terms of downregulated proinflammatory and angiogenic cytokines [ 40 , 90 ]. Moreover, the drugs exhibited low or no systematic toxicity in mouse models. Their effect has been comparatively evaluated to be the same as that of the currently in-use drug trifluoro thymidine (TFT) against HSV-1. The therapeutic effects have largely been shown to reduce infection symptomology in animal models [ 40 , 90 ].

AC-8-Potential Cationic Peptide

AC-8 is an igG FAB fragment that exhibits antiviral properties by binding to the glycoprotein D receptor [ 57 ]. This drug has shown efficacy in terms of reducing corneal vascularization and keratitis in mouse models. This property is produced due to the essential role of Gd in the herpes virus entry mechanism, which AC-8 successfully targets to prevent a subsequent infection. It also reduces cytotoxicity and inflammation even after repeated usage [ 25 , 37 , 56 ].

3.4.2. Nucleic Acid-Based Molecules

Aptamers are compounds that can bind with targeted molecules with a high affinity. They have characteristic features similar to antibodies; they fold in a different sequence-specific conformation determined by the target agents [ 91 ]. Several aptamer compounds have been proposed as antiviral agents in different infectious diseases, including HIV, cytomegalovirus, and recently against glycoproteins of HSV viruses [ 61 ]. RNA aptamers are major candidates under study that exhibit the antiviral potential to neutralize HSV species. Their highly specific nature allows scientists to define and manufacture specifically targeted aptamers that do not show a reaction against other viruses [ 61 , 91 , 92 ].

Dermaseptins

These form a family of associated poly cationic peptides derived from frog species. They exhibit antiviral properties against HSV species [ 93 ]. They interfere with the virus–host interaction owing to the positively charged amino acids that bind with the opposing negative charged heparin sulfate molecules of host cells [ 36 , 55 , 56 , 93 ]. Experiments showed they were effective against acyclovir-resistant HSV-1 species and had a reduced cytotoxic profile. They work well at low pH levels, which may allow them to remain active in the genital tract [ 55 , 56 ]. Some important cation ion peptides belonging to dermaseptins are indicated in Table 2 .

3.4.3. Viral Glycoprotein Targeting Therapeutics

As explained earlier, virus surface glycoproteins play an important function in fusion and viral entry into the host cell. They are positively charged molecules; hence, polyanionic compounds with negative charges could be designed and used to inhibit HSV fusion and replication in vitro by targeting the glycoprotein/sulfate compound complex [ 27 , 30 , 31 , 32 ]. Some important polyanionic compounds that have been used in research experiments are described briefly below.

Nanoparticles with Affinity to Bind GPs

Recent advances in nanotechnology-based therapeutics have presented newer methods for tackling viral infections. Hence, various experiments have been designed that may inculcate the properties of metallic nanostructure-based compounds with high affinity to bind viral glycoproteins [ 94 , 95 ]. As the virus binds to the HS with its surface gPs, a strategy could be devised simply by targeting the gPs. Some important nanoparticle species such as gold nanoparticles (AuNPs), tin oxide (SnO), zinc oxide (ZnO), mercaptoethane sulfonate (Au-MES), and some other important species are under research [ 94 , 95 , 96 , 97 ]. Moreover, the latest studies have demonstrated dual effectivity in terms of viral fusion inhibition and immune stimulation to protect against viral diseases. The overall effect is reduced virus entry, replication, transmission, mutation, and highly induced immune response against these virus infections. Moreover, the conjugation with other drugs and adjuvants may also provide added value to antiviral therapeutics [ 94 , 96 ].

K-5 and SP-510-50 Compounds

Since the presence of HSV-2 infection increases the likelihood of catching HIV-1 infection, therapeutics are being designed for a combined and simultaneous effect against both. In this regard, polyanionic K-5 compounds present a major therapeutic option to address this issue [ 30 , 31 ]. They work by inhibiting free virion infection by interfering with GPs and subsequently preventing cellular cross-transmission in vitro. With more advanced clinical experimentation, these compounds could be used against the sexual transmission of HSV and HIV diseases [ 48 ]. Similarly, SP-510-50 works as an antibody toward the gD of virus particles and, thus, provides antiviral infectivity in HSV patients. Their effect is bound to their dosage applicability for infection prevention [ 85 , 89 ]. They exhibited twofold better results compared to the commercial trifluoridine (TFT) using a lower dose. Moreover, the overall disease symptomology was reduced by their application [ 38 ].

Dendrimers are composed of an amino-acid or carbohydrate conformation that is arranged in macromolecular compositions. Like nanoparticles, they exhibit good antiviral activities for their size [ 58 ]. Moreover, their characteristics, such as ease of preparation, ability to display a wide variety of surface molecules, easier functionalization, and targeted effect against viral gPs and the host cell surface make them an important therapeutic candidate for HSV treatment [ 31 ]. The surface characteristics make them eligible to bind multiple drug regimens, with a high and multidrug payload. Their successful application against HSV is in research annals. The purpose of these trials is to properly establish the safety, tolerability, toxicity, and systematic pharmacokinetic properties of these agents [ 31 , 58 ]. Some important ongoing trials are shown in Table 2 .

3.4.4. Targeting the Downstream Signaling Cascades

Targeting various downstream molecules that conduct cell signaling to induce viral infection is an important strategy that has been the focus of cell biology and bioinformatics recently. These studies allow the exploration of wide-spectrum molecular entities that could be used to design targeted therapies [ 98 ]. For example, studies have demonstrated the mechanism of different viruses that use actin and myosin-dependent pathways for the internalization of viruses in the cell [ 99 ]. The same property is exhibited by HSV which is involved in phagocytic uptake by corneal fibroblasts and retinal epithelial cells [ 98 , 100 ]. The underlying mechanisms are controlled by various kinases such as cyclic AMP-dependent protein kinase A, Akt/PKB, and ribosomal kinases p70 and p85, which play important roles in establishing cellular fusion [ 98 , 99 , 101 ]. Thus, inhibitor therapies are being designed against PI3K kinases to regulate the cellular surfing, entry, and viral infection in targeted cells. Successful results have been acquired in vitro, while next-level studies are still ongoing.

3.5. Antimicrobial Peptides against HSV

Antimicrobial peptides (AMPs) are positively charged short oligopeptides found in virtually all organisms which exhibit diversity in structure and function. They are synthesized and processed to play a vital role in initial immune responses against injury and infections. Some examples of such AMPs in humans include defensins, transferrins, hepcidin, cathelicidins, human antimicrobial proteins, histones, AMP-derived chemokines, and antimicrobial neuropeptides. AMPs have widely been studied for their potential antiviral properties. Defensins have been shown to play a protective role against HSV by blocking virus entry and other stages of the virus life cycle [ 102 , 103 ]. Several studies have shown a vital role of AMPs against various viral infections; therefore, AMPs can be effectively used as excellent therapeutic agents against HSV [ 104 ].

3.6. Some of the Latest Therapeutic Options

3.6.1. compounds derived from marine resources (algal species).

The widespread HSV positivity in the human population has compelled the scientific community to continuously remain engaged in proposing different therapeutic regimens against HSV infections [ 21 , 46 , 48 ]. The traditionally used drugs such as acyclovir, ganciclovir, valaciclovir, and foscarnet are good options for HSV treatment; however, the development of drug resistance in patients and the ability for viruses to develop a mutation in strains has compelled scientists to look for other options [ 105 ]. Marine-based products, such as those derived from algal populations, bacterial species, fungal biomass, sponges, tunicates, echinoderms, and mollusk seaweeds, are important organisms from which these drug candidates are being derived [ 105 ]. Caulerpin is one of such candidate drugs that has its origin in marine algae and works well as an antioxidant, antifungal, antibacterial agent, and acetylcholinesterase (AChE) inhibitor [ 106 ]. It functions to inhibit the stages of the replication cycle [ 107 ]. Moreover, its application as an alternative to traditional acyclovir is under consideration. In addition to caulerpin, various other algal species (~40) are in research and development for exhibiting anti-HSV properties in resistant infections. They exhibit antiviral activity ranging from 50% to 80% for both species of HSV [ 21 , 46 , 48 , 105 , 106 ]. Different algae with antiviral properties are shown in Table 2 . These studies allow the scientific community to delve deeper into marine-based and plant-based products to find a cure for HSV.

3.6.2. Mucus Penetrating Particles

Since mucus formation is an unfortunate characteristic of the common summer cold, concurrent HSV and common cold infections could present a hurdle in drug delivery and penetration of the targeted cells [ 95 ]. Owing to the mucoadhesive characteristics exhibited by common drugs, some studies have been conducted to design mucous penetrating particles mainly based on nanoparticles. These neoformations easily penetrate the tissues of the sinuses and vagina and, thus, establish successful delivery of drugs to tissues of interest [ 95 , 96 ]. Moreover, they provide the opportunity to surface coat the particles with multiple antiviral drugs and enable better absorption of the nanosized particles for a more profound effect. Overall, MPPs improved drug binding, distribution, retention, and dosages, as well as reduced toxicity, in HSV model experiments [ 95 , 96 , 108 ].

3.6.3. Plant-Derived Therapeutic Options

Similar to algal-derived drug candidates, some recent studies have indicated the therapeutic potential of some plant-based products ( Table 2 ). Like other drug regimens, they inhibit the virus entry and replication cycle by acting as potent inhibitors of various glycoproteins specific to different antiviral plant agents [ 109 ]. Antiviral agents such as neem bark extract (NBE) derived from Azardirachta indica and cyanovirin-n (CV-N) derived from Nostoc ellipsosporum, as well as peri-acylated gossylic nitriles derived from gossypol, are some of the important drug candidates exhibiting efficient anti-HSV profiles [ 42 , 47 , 48 , 109 , 110 ]. However, the potent anti-HSV profiling, toxicity studies, pharmacokinetic profiling, and antidrug comparative studies remain to be conducted in detail to provide the benefits associated with plant-based herbal therapies [ 109 ].

3.6.4. Combined Therapies

Knowing the scope of HSV disease implications, scientists are now gathering their research focus toward combined therapies since a certain specific drug or vaccine has not yet been shown to eradicate HSV infection [ 21 , 30 , 48 , 61 ]. Therefore, more integrated and coordinated efforts are being put forth in the form of combined therapies, where several drug combinations are checked for their effect against HSV. Most of the individual drug regimens have already gone through scientific examination to establish their antiviral character. Hence, the purpose of combined therapies is to only evaluate multiplex combined antiviral effects against HSV infection [ 46 , 48 ]. Various experiments in research annals have been carried out in vitro, in animal models, and in clinical trials. Similarly, more specific studies are in the research phase against proven anti-HSV drugs such as acyclovir and acycloguanosine in terms of evaluating their cytotoxic and pharmacokinetic profiles and upgrading them by nano-scaling or conjugating with nanoparticle formulations for effective low dosage implications [ 59 , 94 , 95 , 96 , 97 ]. These latest studies have provided a doorway to the resistance that develops over time in patients. The new formulation offers lower dosage, more targeted delivery, and enhanced efficacy in tested subjects. Therefore, the field of combined therapy against HSV is a major player in the future drug and vaccination designs against HSV. A brief overview of these therapeutic strategies against HSV have been covered in a summarized version in Table 2 below.

Ongoing trials for HSV drugs.

4. Conclusions

Several vaccines and drug trials are in progress against HSV. They provide a promising therapeutic potential in individual studies. However, no profound and specific therapy has been established until now that could tackle the problem of HSV infection worldwide. The need is to establish more coordinated and integrated studies with the cooperation of scientists, doctors, and pharmacies to take drug testing one step ahead in clinical practice. This is important because the expected viral mutations present the threat of the development of another mutant HSV that could then become another complication for HSV treatment and prevention. Therefore, the most effective approach for future therapeutic development will be to develop modern drug-design approaches such as those based on plant products and nanotechnology, and to carry out more combined therapies for large-scale and broad-spectrum antiviral and immunostimulatory effects so that HSV complications can be successfully addressed in the coming years.

Abbreviations

Funding statement.

This research received no external funding.

Author Contributions

Conceptualization, S.M. and Y.W.; methodology, S.M., R.S., K.M. and Y.W.; validation, S.M., O.A., R.S. and K.M.; formal analysis, S.M., O.A., R.S., K.M. and Y.W.; resources K.M. and Y.W.; data curation, S.M., O.A., R.S., K.M. and Y.W.; writing—original draft preparation, S.M.; writing—review and editing, S.M., K.M. and Y.W.; supervision, Y.W.; project administration, Y.W. funding acquisition, Y.W. All authors have read and agreed to the published version of the manuscript.

Institutional Review Board Statement

Informed consent statement, data availability statement, conflicts of interest.

The authors declare no conflict of interest.

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

• Alzheimer's disease & dementia
• Arthritis & Rheumatism
• Attention deficit disorders
• Autism spectrum disorders
• Biomedical technology
• Diseases, Conditions, Syndromes
• Endocrinology & Metabolism
• Gastroenterology
• Gerontology & Geriatrics
• Health informatics
• Inflammatory disorders
• Medical economics
• Medical research
• Medications
• Neuroscience
• Obstetrics & gynaecology
• Oncology & Cancer
• Ophthalmology
• Overweight & Obesity
• Parkinson's & Movement disorders
• Psychology & Psychiatry
• Radiology & Imaging
• Sleep disorders
• Sports medicine & Kinesiology
• Vaccination
• Breast cancer
• Cardiovascular disease
• Chronic obstructive pulmonary disease
• Colon cancer
• Coronary artery disease
• Heart attack
• Heart disease
• High blood pressure
• Kidney disease
• Lung cancer
• Multiple sclerosis
• Myocardial infarction
• Ovarian cancer
• Post traumatic stress disorder
• Rheumatoid arthritis
• Schizophrenia
• Skin cancer
• Type 2 diabetes
• Full List »

share this!

August 8, 2023

This article has been reviewed according to Science X's editorial process and policies . Editors have highlighted the following attributes while ensuring the content's credibility:

fact-checked

peer-reviewed publication

trusted source

New molecule could treat shingles, herpes viruses

by Leigh Beeson, University of Georgia

You've seen the commercial. The one that ominously tells you if you had chickenpox as a child, the virus that causes shingles is already inside you.

It's creepy, but it's also a good way to prompt people to get the shingles vaccine. Unfortunately, the shot doesn't always keep you from getting shingles. It just mitigates the symptoms.

That's why University of Georgia researchers David Chu and Uma Singh have developed and patented a molecule to serve as a potential treatment for the varicella zoster virus , the type of herpes that causes both chickenpox and shingles.

A new study published in the Journal of Medicinal Chemistry found the molecule can effectively treat the uncomfortable lesions that accompany shingles and suggests the molecule may also work against the viruses that cause oral and genital herpes.

"Many viruses are becoming drug-resistant to the current medications on the market," said Uma Singh, lead author of the study and a lecturer in UGA's College of Pharmacy. "There is a continuous need for new molecules , and the one we developed, called POM-L-BHDU, shows much more potency against the virus than current ones."

The researchers also found that the molecule is safe for treating varicella zoster virus in cancer patients .

Additionally, the molecule can be applied topically in addition to being taken orally or intravenously, making it a great option for a future cream-based medication for both shingles and other herpes outbreaks.

No effective treatments exist for herpes, shingles viruses

While several drugs are on the market to treat the viruses caused by the varicella zoster virus, they aren't particularly effective or can have potentially life-threatening side effects.

For example, cidofovir is an antiviral commonly used for viral eye infections and used off-label to treat warts and herpes. But it can accumulate in the kidneys and potentially cause them to fail in severe cases.

A topical medication using the patented molecule can better target localized outbreaks, preventing the virus from spreading to other areas of the body. Topical medications also limit the amount of a drug that is absorbed into the bloodstream and cut down significantly on side effects.

"We want to develop this as a broad-spectrum molecule," Singh said. "It acts against both the varicella zoster virus and herpes simplex 1 and 2 viruses. For patients who want to take it in capsules, they could. Those who want to take it intravenously, they could. And those who want to use it topically, they can easily apply it at home."

The researchers hope the topical formula will be sold over the counter, enabling patients to easily access treatment in the privacy of their own homes without needing a prescription.

Molecule shows success against viruses in multiple models

The molecule has already proven effective in vitro and in vivo mouse models.

Topical studies on adult human skin indicate that POM-L-BHDU, 0.2% formulated in cocoa butter is highly effective against both herpes simplex 1 and the varicella zoster viruses. (These results are currently unpublished.)

The next step is to get the molecule into phase 1 clinical trials , something Singh hopes will happen in the next couple of years.

"We want to push this project as soon as possible into large-scale synthesis," Singh said. "It has the potential to benefit society on a large scale."

Recently, the UGA Research Foundation has licensed this molecule to a company called Anterogen Co.

Explore further

Feedback to editors

New tool detects signs of motor neuron disease before symptoms begin

16 minutes ago

Study suggests maintaining optimism contributes to better mobility in women as they grow older

18 minutes ago

Single genomic test promises accelerated diagnoses for rare genetic diseases

26 minutes ago

Study examines facilities' low use of monthly injections for treating opioid addiction

Clinical trial: Some sarcoma patients improve with T cell immunotherapy

27 minutes ago

New technology could revolutionize valvular heart disease care

29 minutes ago

Brain circuit that spoils appetite identified

33 minutes ago

Patients with delirium more likely to develop dementia, finds study

35 minutes ago

New tool provides researchers with improved understanding of stem cell aging in the brain

38 minutes ago

Scientists take a closer look at pulmonary fibrosis genetics

44 minutes ago

Related Stories

Chicken pox vaccine linked with shingles at the vaccination site in some children.

Feb 9, 2018

Adult exposure to chickenpox linked to lower risk of shingles, but does not provide full protection

Jan 22, 2020

Shingles vaccine reduces risk of stroke and heart attack from virus, study suggests

Jul 24, 2023

Shingles vaccine important for older adults

Dec 4, 2017

Shot may protgect against shingles

Feb 19, 2018

Q and A: Shingles: Not just a band of blisters

Nov 29, 2022

Recommended for you

Familial Alzheimer's disease transferred via bone marrow transplant in mice

48 minutes ago

Statistical machine learning can find unknown factors that cause disease

21 hours ago

Combining epigenetic cancer medications may have benefit for colorectal cancers and other tumor types

Investigating the loss of musical ability

19 hours ago

Sex-specific blood biomarkers linked to memory changes in middle-aged adults: The Framingham heart study

22 hours ago

Let us know if there is a problem with our content

Use this form if you have come across a typo, inaccuracy or would like to send an edit request for the content on this page. For general inquiries, please use our contact form . For general feedback, use the public comments section below (please adhere to guidelines ).

Please select the most appropriate category to facilitate processing of your request

Thank you for taking time to provide your feedback to the editors.

Your feedback is important to us. However, we do not guarantee individual replies due to the high volume of messages.

E-mail the story

Your email address is used only to let the recipient know who sent the email. Neither your address nor the recipient's address will be used for any other purpose. The information you enter will appear in your e-mail message and is not retained by Medical Xpress in any form.

Newsletter sign up

Get weekly and/or daily updates delivered to your inbox. You can unsubscribe at any time and we'll never share your details to third parties.

More information Privacy policy

Donate and enjoy an ad-free experience

We keep our content available to everyone. Consider supporting Science X's mission by getting a premium account.

E-mail newsletter

Clinical Trials

Vaccine info, herpes vaccine candidates, herpes vaccines 2024.

Developing protective herpes simplex virus ( HSV ) vaccines has been an ongoing challenge for decades. HSV is highly adapted to evade host immunity, making it difficult for a vaccine to prevent the virus from reaching the ganglia , which is the site of latency . Various herpes vaccine candidates are based on DNA, modified mRNA, protein subunits, killed virus, and attenuated live virus vaccine technologies . In addition, the World Health Organization ( WHO ) published its preferred product characteristics for Alpha (α)-herpesviruses  vaccines and updated its pipeline review . As of March 2024, the U.S. Food and Drug Administration ( FDA ), Brazil ,  Canada , China ,  Europe , India , Japan , and the U.K.  had not authorized preventive or therapeutic herpes vaccines. 

The U.S. Department of Health and Human Services ( HHS ) invited stakeholders on February 6, 2024, to provide written public comments on the draft  HSV Addendum  to the  STI National Strategic Plan . The deadline for comment submission to HHS is February 16, 2024.

When developing herpes vaccines, candidates conduct clinical trials  called phase 1, phase 2, phase 3, and phase 4. Each development phase is essential. The  WHO , the U.S. National Instuties of Health ( NIH ), and global partners launched  STI Watch , a portal containing updated information on vaccine development status. Both preventive and therapeutic  HSV  vaccines are being explored. This HerpesFolds table gives interactive access to all AlphaFold structures of HSV-1 strain 17 (Uniprot proteome UP000009294 ), HCMV strain Merlin ( UP000000938 ), EBV strain B95-8 ( UP000153037 ), as well as KSHV strain GK18 ( UP000000942 ), visualized by 3Dmol.js. The AlphaFold includes two additional Herpesviruses: PrV ( UP000154030 ) and MHV68 ( UP000099649 ).

Current herpes vaccine candidates in clinical trials include:

Herpes Simplex Virus-targeted immunotherapy ( HSVTI ) is conducting a phase 1/2 clinical study  of targeted immunotherapy ( GSK3943104A ) against HSV in healthy participants aged 18-40 years or in participants aged 18-60 years with recurrent genital herpes.

mRNA-1608 is an mRNA vaccine candidate against HSV-2 disease. The mRNA-1608-P101 phase 1 study launched on September 6, 2023, and is forecasted to be completed on June 4, 2025. With mRNA-1608, Moderna Inc.  aims to induce a strong antibody response with neutralizing and effector functionality combined with cell-mediated immunity. Independent Study : An mRNA vaccine to prevent genital herpes. Moderna stated on September 13, 2023, that the latent and other vaccine market is estimated at approximately $10 billion to $25 billion.

BNT163 is an mRNA-based HSV vaccine candidate that encodes three HSV-2 glycoproteins to help prevent HSV cellular entry and spread and counteract HSV immunosuppressive properties of HSVs.  Prof. Dr. Harvey M. Friedman , Professor of Infectious Diseases at the University of Pennsylvania Perelman School of Medicine ,   conducted preclinical and scientific research on HSV. In the  phase 1 clinical trial, the first subject was dosed in December 2022, and the safety, tolerability, and immunogenicity of BNT163 were evaluated. The last study update was posted on January 5, 2023.

Rational Vaccines's  VC2 vaccine candidate is a live-attenuated  vaccine targeting facial, ocular, and genital herpes caused by HSV-1 and potentially protects against genital herpes caused by HSV-2. On October 13, 2023 , Rational Vaccines was awarded $2.8 million by the U.S. National Institute of Health, and in a  2018 study  conducted at Louisiana State University, Brent Stanfield and colleagues examined the immune response generated by intramuscular injection of the VC2 vaccine in the guinea pig.

Delta gD-2  (∆gD-2) is a vaccine candidate based on an HSV-2 virus genetically deleting  glycoprotein D (gD-2) . 

HSV529  (HSV15) is a vaccine candidate classified as a replication-defective virus, meaning the virus possesses all the wild-type HSV virus components except two proteins, UL5 and UL29, involved in viral DNA replication.  This phase 1/2 study was last updated on January 13, 2021, by  Sanofi Pasteur and the National Institute of Allergy and Infectious Diseases.

EXD-12 is a vaccine candidate currently in preclinical testing for safety and efficacy as a prophylactic and therapeutic vaccine for herpes simplex virus 1 (HSV-1) and herpes simplex virus 2 (HSV-2). 

NanoVax is an adjuvant platform to develop a vaccine candidate to protect against the two viruses that can cause genital herpes.

RVx201  is a live-attenuated HSV-2 vaccine candidate conducting an observational clinical study  RVx-001-PSS in England designed to have a specific degree of attenuation through specifically designed mutations in the ICP0 protein.

Shanghai BD Gene is conducting a  phase 1/2 clinical study  in humans. It is the only gene-editing technology for Cas9 mRNA delivery by lentivirus .

Assembly Biosciences, Inc.  announced data from development candidate ABI-5366 , a long-acting HSV helicase inhibitor targeting high-recurrence genital herpes.

Repurposed BCG Vaccination Targeting Herpes

The Bacillus Calmette-Guérin ( BCG ) vaccine is an approved attenuated vaccine for tuberculosis prevention. Research published by The Lancet in 2023 suggests that BCG vaccination induces three non-specific immune responses: trained immunity, heterologous immunity, and anti-inflammatory effects. These immune responses have been used to prevent and treat various diseases, including HSV-1. In the journal eClinicalMedicine , Laure F Pittet and colleagues published their phase 3 clinical trial results conducted across multiple countries to assess the impact of BCG vaccination on recurrent herpes labialis. The BRACE trial ( NCT04327206 ) concluded that BCG-Denmark vaccination had a beneficial effect on herpes labialis, particularly in males with frequent recurrences. Still, it may increase the risk of a first cold sore.

A  systematic review of Medline, EMBASE, and PubMed was published in September 2020 that concluded BCG vaccination has a potential, safe, affordable, and readily available candidate intervention to decrease the high burden of disease associated with HSV infection and recurrences but adequately controlled randomized trials are required.

Herpes Vaccine Preclinical Development

Redbiotec is currently developing an HSV-2 therapeutic vaccine (immunotherapy). Their vaccine program is T-cell-mediated protection and aims to outperform antivirals and allow patients to stay symptom-free for >12 months with two injections.

Eurocine Vaccine vaccine candidates against HSV-2 - in a non-human study, mRNA vaccination stimulated potent T cell responses that significantly outcompeted those generated by the protein vaccine in performance in several specific areas. Dr. Karl Ljungberg, Director of Preclinical Development at Eurocine Vaccines, stated in December 2022, "The T cell responses that we report here align with those that can be detected after recovery from an infection and are focused on the part of the HSV-2 virus that we believe is important to target to obtain immunologic control of the virus."

Researchers designed and constructed an HSV-1 synthetic platform based on H129 -G4. This platform could facilitate further manipulation of the HSV-1 genome for developing neuronal circuit tracers, oncolytic viruses, and vaccines.

The journal MDPI published an article on July 18, 2023, that concluded B7 costimulation molecules expressed from a replication-defective vaccine can enhance vaccine efficacy, even in an immunocompetent host.

Herpes Vaccine Clinical Trials

Sponsored clinical trials recruit  prospective participants in various studies.  Herpes Cure Advocacy launched Herpes Cure Pipeline 2.0 ( March 2022 ), which tracks preclinical and clinical study timelines and strategies globally.

Herpes Testing

The JAMA Network published on February 14, 2023, that the U.S. Preventive Services Task Force recommends against routine serologic screening for genital HSV infection in asymptomatic adolescents and adults, including pregnant women, as neonatal herpes infection is uncommon. (D recommendation).

Herpes Treatments

Herpes treatments are available in 2024. However, these products do not cure herpes.

HSV-2 Preventive Gel Clinical Development

Researchers announced  in September 2022 that they had developed a gel-based lubricant that can potentially prevent individuals from being exposed to HSV-2. Cow mucus provides the basis for a synthetic prophylactic gel developed at the KTH Royal Institute of Technology to protect against herpes transmission. Advanced Science published this Research Article on September 14, 2022. The researchers  synthesized BSM gels that liquefied under large strain and self-healed rapidly and repeatedly after the strain was removed. They showed that these properties were essential for mucin lubrication, as evidenced by significantly improved lubrication by the mucin gels (5%, wt/v) compared to mucin solutions (5%, wt/v). They also showed that the gels inhibited the infection of HSV-2 in epithelial cells and immune cells by about 80%.

Hongji Yan, a biomaterials researcher at KTH, commented in a media statement the promising results raise hope that when it becomes available as a product, the gel could help reverse troubling trends in the spread of sexually transmitted infections. 

Genital Herpes Serologic Screening

The U.S. Preventive Services Task Force (USPSTF)  recommends against routine serologic screening for genital herpes simplex virus infection in asymptomatic adolescents and adults, including pregnant women. As of August 16, 2022, recommendations made by the USPSTF are independent of the U.S. government. 

Because of the poor performance , a high rate of false-positive test results of commercially available U.S. FDA-approved HSV tests , and the limited availability of confirmatory testing, prevention efforts for herpes transmission have been insufficient. The CDC's  Office of Science  issued a Broad Agency Announcement  in December 2022 for the competitive selection of research proposals, including an RFP for serologic tests for HSV, reported  Herpes Cure Advocacy ,

Sexually Transmitted Disease Vaccines

As of 2024, Sexually Transmitted Disease vaccine news is posted at Precision Vaccinations .

Herpes Vaccine News

February 12, 2024 - Researchers at Dartmouth's Geisel School of Medicine and Thayer School of Engineering published a new study in Cell Reports Medicine, offering insights into how antibodies function in combating HSV infections. 

December 14, 2023 - Harvard News - New study (Oct. 26, 2023) findings could inform the design of treatments for various viruses that replicate in the cell nucleus.

November 1, 2023 - The University of Pittsburg School of Medicine received a grant of $504 thousand to conduct innovative herpes research.

October 13, 2023 - Rational Vaccines was awarded $2.8 million in U.S. National Institute of Health funding in three separate grants to further its research to diagnose, treat, and prevent the spread of HSV.

September 30, 2023 - A Systematic Review was published: The Association Between Herpes Simplex Virus and Alzheimer's Disease.

May 25, 2023 - Akiko Iwasaki, Ph.D., Sterling Professor of Immunobiology and professor of dermatology, molecular, cellular & developmental biology, and epidemiology (microbial diseases) at Yale School of Medicine, developed a therapeutic vaccine candidate that may reduce the reactivation of genital herpes in guinea pigs. However, lack of investment has hindered human clinical trials.

April 21, 2023 - The NIAID announced a Request for Information on the U.S. National Institutes of Health's vital strategic approaches to developing an HSV Strategic Plan.

April 5, 2023 - The WHO published updated Herpes Facts, including an HSV-2 infection increases the risk of acquiring HIV.

March 20, 2023 - Research Article: Construction and characterization of a synthesized herpes simplex virus H129-Syn-G2.

December 21, 2022 -  BioNTech S.E. announced that the initial subject was dosed in a first-in-human Phase 1 clinical study of BNT163, an HSV prevention vaccine candidate.

December 20, 2022 - Eurocine Vaccines announced the mRNA vaccine generates superior T-cell responses. Dr. Karl Ljungberg, Director of Preclinical Development at Eurocine Vaccines, stated, "The T cell responses that we report here are in line with those that can be detected after recovery from an infection and are focused to a part of the HSV-2 virus that we believe is important to target to obtain immunologic control of the virus."

December 15, 2022 - A study published by the peer-reviewed journal PLOS Medicine conducted if HSV-2 has indeed contributed to the transmission of HIV, then nearly one-third of antiretroviral costs and HIV-related wage losses add to herpes-related costs. Given the magnitude of the combined losses, a vaccine against HSV-2 must be a global priority.

December 12, 2022 - The Lancet Europe published a systematic review, meta-analyses, and meta-regressions on the epidemiology of HSV-2 in Europe.

December 9, 2022 - The journal Nature published an article: Urgency and necessity of Epstein-Barr virus (EBV) prophylactic vaccine development. EBV is a γ-herpesvirus that contains a double-stranded DNA genome and is the first identified human oncogenic virus. The EBV, also known as human herpesvirus 4 , is a member of the herpes virus family, says the U.S. CDC .

October 27, 2022 - Contagion (Vol. 07, No. 5) - Revisiting Old Foes: Updates on HSV.

October 22, 2022 - The JAMA Network published an Original INvestigation - Viral Shedding 1 Year Following First-Episode Genital HSV-1 Infection - that concluded genital HSV-1 shedding declined rapidly following an initial infection and during the first year.

October 6, 2022 - Wiley Online published a case report on herpetic endotheliitis and stromal keratitis following inactivated COVID-19 vaccination. This is the first report of herpetic endotheliitis and stromal keratitis following the BBIBP vaccine. Although the temporal link between vaccination and adverse ocular events, including HSV-1 reactivation, cannot be established through these case reports, these reports add to the sparse body of evidence supporting this notion. 

September 26, 2022 - The Fred Hutchinson Cancer Center in Washington announced researchers (Drs. Keith Jerome and Martine Aubert) found substantial reductions in oral and genital viral shedding in the treated mice, with many of those treated showing no detectable virus shed. A related non-peer-reviewed study was also published: AAV-delivered gene editing for latent genital or orofacial herpes simplex virus infection reduces ganglionic viral load and minimizes subsequent viral shedding in mice.

September 23, 2022 - Nature - Scientific Reports published: HSV-1 0∆NLS vaccine elicits a robust B lymphocyte response and preserves vision without recognizing t HSV-1 glycoprotein M or thymidine kinaon. Collectively, the results suggest (1) the live-attenuated HSV-1 mutant 0∆NLS elicits a robust B cell response that drives select B cell responses more significantly than the parental HSV-1 and (2) HSV-1 TK and gM are likely expendable components in the efficacy of a humoral response to ocular HSV-1 infection.

September 19, 2022 - Virios Therapeutics, Inc. announced topline results from its Fibromyalgia Outcome Research Trial Evaluating Synergistic Suppression of HSV-1 study of oral IMC-1 for the treatment of F.M. "We believe the interplay between different COVID-19 strains and herpes virus activation may be contributing to the differential response we observed in patients enrolled in 2021 versus 2022," stated Greg Duncan, Chairman and CEO of Virios Therapeutics.

August 19, 2022 - The journal Neurology published a RESEARCH ARTICLE: Herpes Viruses: Associations With Brain Volumes, Cognitive Performance, and Plasma Biomarkers. Discussion. These findings suggest an association of symptomatic herpes virus infection with white matter volume loss, attentional decline, and astrogliosis.

August 15, 2022 - Rational Vaccines announced the launch of an observational clinical study  of RVx201  in the U.K. on August 3, 2022, that will recruit about 200 participants. In addition to assessing the typical baseline characteristics of the population, the purpose of this study is also to determine the acceptance of clinical trial procedures and understand the interest of the target patient population to participate in a therapeutic Phase 1/2 HSV-2 vaccine study.

July 8, 2022 - Rational Vaccines announced findings from a U.S. NIH-funded pilot study of RVX201 that showed that it reduced recurrent genital lesions compared to the gD2-alum/MPL vaccine or placebo in vivo. In addition, RVX201 appears to generate a robust cellular immune response equivalent to that elicited by wild-type HSV-2 on Day 7 post-infection.

June 16, 2022 - Eurosurveillance reported researchers in Austria had identified a second strain of extensively drug-resistant gonorrhea. 'We describe the second global XDR N. gonorrhoeae strain, with high-level resistance to azithromycin and resistance to ceftriaxone, cefixime, cefotaxime, ciprofloxacin, and tetracycline, which caused a possible gonorrhea treatment failure with ceftriaxone (1 g) plus azithromycin (1.5 g).

June 14, 2022 - Eurocine Vaccines AB announced that it entered into a research and collaboration agreement with Redbiotec AG that transfers the exclusive global rights to develop, manufacture, and commercialize vaccine candidates against Herpes Simplex Virus Type 2, HSV-2, based on the technologies developed by Redbiotec .

June 1, 2022 - Virios Therapeutics, Inc. announced the results of a pilot study performed at the University of Alabama, titled "Gastric Herpes Simplex Virus Type 1 Infection is Associated with Functional Gastrointestinal Disorders in the Presence and Absence of Comorbid Fibromyalgia: A Pilot Case-Control Study", were published in the journal Infection in April 2022. These results provide evidence for a potential mechanistic connection between active herpes virus infection and functional gastrointestinal Disorders ("FGID"), with or without comorbid fibromyalgia ("F.M."), as well as the potential for combination antiviral therapy to treat patients with FGIDs and F.M.

May 11, 2022 - Peer-review study: The health impact of seven herpesviruses on (pre)diabetes incidence and HbA1c: results from the KORA cohort. Conclusion: HSV2 and CMV serostatus associations with (pre)diabetes incidence indicate that these herpesviruses may contribute to impaired glucose metabolism.

April 25, 2022 - Frontiers Immunology published: Combinatorial Herpes Simplex Vaccine Strategies: From Bedside to Bench and Back. 'We discussed that a prime/pull vaccine strategy using asymptomatic epitopes, combined with immune checkpoint blockade, would be a successful herpes vaccine approach.'

January 25, 2022 - PNAS published a study that developed a parameterized model predicting how much and how rapidly a betaherpesvirus-vectored transmissible vaccine can be expected to reduce the prevalence of a target pathogen. The study concluded, 'Our models are focused on transmissible vaccines designed using herpes virus vectors and demonstrate that these vaccines—currently under development for several important human pathogens—may have the potential to control zoonotic pathogens within the reservoir hosts rapidly. However, our study results suggest that the effectiveness of MCMV-vectored transmissible vaccines may depend on the virus strain used to construct the vaccine and the target population into which the vaccine is ultimately deployed.'

November 22, 2018 - Study: The live attenuated prophylactic HSV vaccine, VC2, was effective in the guinea pig model of genital HSV-2. Its decreased ability to infect neural tissues provides advantages over live attenuated vaccines. The live attenuated prophylactic HSV vaccine, VC2, was effective in the guinea pig model of genital HSV-2. Its decreased ability to infect neural tissues provides advantages over live attenuated vaccines.

January 9, 2014  - Review: The challenge of developing herpes simplex virus 2 vaccines.

Content sources include the  WHO, US CDC, NIH, research papers, ClinicalTrials.gov, and the Precision Vaccinations news network. Healthcare providers, such as Dr. Robert Carlson, fact-check content.

No clinical trials found

Fact checked by Robert Carlson, MD

Fact checked by Danielle Reiter, RN

BREAKING: FTX founder Sam Bankman-Fried sentenced to 20 years for fraud scheme

With a herpes vaccine on the horizon, will the stigma persist?

When I was 9 years old, I came down with a terrifying bout of pneumonia and ended up in the hospital for a week. I remember having a panic attack when I couldn’t catch my breath and my mother, scared, called a doctor for help. He arrived quickly and calmed me down with his gentle bedside manner. He helped me take deep, slow breaths through an oxygen mask, to the tune of his voice as he counted down from 10. I egged myself on, knowing I had to relax or I’d get transferred to the local children’s hospital.

A few days later, I arrived back at school. I was in fourth grade. I had recovered but still had trouble breathing. Whenever my immune system runs low, I’m at greater risk for a herpes outbreak , and that’s exactly what happened. My face had erupted in giant, oozing cold sores. During recess, I sat on a bench alone listening to Coldplay’s “Yellow” on my Walkman. A group of older, prettier and more popular girls approached me. I pulled one of my earbuds out to hear what they were saying, only to find they were taunting me. “AIDS Face.” “Pimple Mouth.” “Zit Lips.” 

I’ve had herpes for as long as I can remember, likely contracting the virus as a grabbing toddler reaching for my mother’s face.

As these cruel names were hurled at me, I trembled, cried and hugged my legs to my chest. When treating cold sores, time is of the essence. The second you feel a tingle, you need to treat the afflicted area. This helps mitigate the severity of the breakout . However, for a period of my childhood, I chose inaction, too traumatized by the stigma to do anything about it anymore. Instead, I leaned into being the weird kid and a social pariah, allowing my face to be riddled with herpes. While being infected with the virus is common and technically not a big deal, I was astronomically ashamed and isolated. In pop culture, the word herpes is near synonymous with dirty and that’s how I felt — dirty.

I’ve had herpes for as long as I can remember, likely contracting the virus as a grabbing toddler reaching for my mother’s face. Over the decades, I have spent a considerable amount of time agonizing over how to skip work, school and social events. When hiding from the world, I have tried every home remedy, topical cream and ointment and antiviral drug available. Sadly, there is no cure for herpes, only options to limit or prevent outbreaks . But a new vaccine on the horizon could prove to be a game changer.

Moderna is developing a vaccine using mRNA technology to treat the herpes simplex virus (HSV). There are two HSV virus types — HSV-1, the one I have, that affects the mouth, face and genitals, and HSV-2, which predominantly affects the genitals. However, both viruses can spread to other parts of the body. In the United States, of people aged 14 to 49, 47.8 percent have HSV-1 and 11.9 percent have HSV-2 , according to the Centers for Disease Control and Prevention. Many people living with herpes don’t know they have it, which means these figures may be far greater. HSV remains latent in the body , staying alive through the lifelong infection of a given person. When reactivated, HSV results in visible outbreaks. The vaccine will protect against HSV-2 and provide cross-protection for HSV-1 as a suppressive antiviral treatment.

The CDC recommends against widespread testing for herpes as, alongside the risk of false positives, “the risk of shaming and stigmatizing people outweighs the potential benefits.” Throughout my life, the social stigma surrounding herpes has proven more disastrous for my mental health than the virus itself. For so long, I assumed I wasn’t likable, let alone loveable. I believed I would be consigned to a life without sex and intimacy, having internalized harmful myths about a generally harmless infection. When I’ve had an outbreak, I’ve often chosen abstinence over disclosure, too fearful of rejection to open up. Interestingly, many people don’t even realize that having had chickenpox or shingles means they’ve been infected by a member of the herpes family . (Moderna is also developing a vaccine that would reduce the rate of the varicella-zoster virus that causes shingles.) But it’s the sexual component of HSV-1 and 2 that remains socially lethal.

The CDC recommends against widespread testing for herpes as, alongside the risk of false positives, “the risk of shaming and stigmatizing people outweighs the potential benefits.”

Much of the hysteria affecting the social status of herpes has been generated by the media and pharmaceutical companies. A 1982 TIME magazine cover labeled genital herpes “Today’s Scarlet Letter.” Authors of the cover story , John Leo and Maureen Dowd, posited that it could cause the sexual revolution to grind to a shrieking halt. Even more dramatic, the story argued that herpes was “altering sexual rites in America, changing courtship patterns, sending thousands of sufferers spinning into months of depression and self-exile and delivering a numbing blow to the one-night stand.”

Given the stigma around HIV at the time, perhaps the increased awareness about herpes did make some people change their sexual behaviors, but we also know that any activity that was deemed sexually deviant was used as a scapegoat to make sex seem shameful. A 2016 Vice exposé found that, starting in the 1970s, there is evidence that “big pharma” likely conjured up and perpetuated stigma to increase sales of a new drug, one that couldn’t be used to treat all members of the herpes family. To advertise the drug, herpes had to be pushed as a disease worthy of attention, the answer to which was a sex panic.

In the age of medical misinformation, vaccines themselves are misunderstood. For example, in general, they have been said to cause autism, despite no scientific evidence. The misinformation seems to increase when it comes to newly available ones; look no further than conspiracy theories swirling around Covid-19 vaccines , which were rumored to contain infertility agents or spread HIV — another notoriously stigmatized STI. The mRNA technology used to create these life-saving Covid-19 vaccines opened up the door for those Moderna is currently developing to treat herpes. In the near future, it’s possible that people will be prevented from ever getting herpes and that those with it won’t have to suffer through outbreaks anymore. I’ve wondered if the social stigma will persist and if kids like myself will be spared the pain I have experienced since childhood.

Deidre Olsen is an award-nominated writer based in Berlin. She is writing a memoir about self-destruction, healing and resilience.

• Share full article

Advertisement

Supported by

To Patients, Herpes Can Be Devastating. To Many Doctors, It’s Not a Priority.

Billions of people live with the infection, but there has been scant progress for treatments and tests.

By Dani Blum

When Lauren went to her doctors with stinging clusters of sores on her genitals, she assumed the pain was from a urinary tract infection. But at the OB-GYN, her doctor swabbed the bumps and told her that the rash was herpes. “No,” she remembered responding. “It’s not.”

At the time, Lauren, who asked that her last name be withheld in order to talk about personal health issues, was a 19-year-old college student. She was in a two-year monogamous relationship with her second-ever sexual partner — a guy who occasionally dealt with an errant blister on his lip.

They hadn’t known that oral herpes could induce cold sores, and that HSV-1, the virus that causes oral herpes, could be transferred to the genitals. Lauren’s boyfriend was convinced that she had cheated on him, and he broke up with her, she said.

Lauren became withdrawn and almost failed out of college. “You think, Why does anything even matter anymore?” she said. “I’m never going to date. I’m never going to have a boyfriend.”

That was in 2013. Over the last decade, Lauren has had only a few additional outbreaks, none as painful as her first. The mental strain — the depression she fell into after the diagnosis, the fear that future partners wouldn’t accept her — has been, by far, the hardest part of managing the disease. “It attacks your self-worth,” she said.

Herpes is extremely common: The World Health Organization estimates that 3.7 billion people live with HSV-1, some oral and some genital. And cases like Lauren’s, where HSV-1 spreads to the genitals during oral sex, have sharply increased over the past two decades, said Dr. Jonathan Zenilman, a professor of medicine at Johns Hopkins University School of Medicine who specializes in sexually transmitted infections.

But herpes isn’t a top priority for researchers, said Dr. Larry Corey, a professor and virologist at Fred Hutch Cancer Center in Seattle who has studied the virus. It isn’t even the top priority among those who study sexually transmitted infections, he added. “The disease has been sort of ignored by both the pharmaceutical industry as well as the medical research establishment,” he said.

There are several potential reasons for this, experts theorize, including the relatively mild physical symptoms for most patients, clinicians’ reluctance to discuss sexual health and how hard it is to develop a vaccine for herpes.

“The fact that a lot of the toll is psychological makes physicians not that interested in it,” said Dr. Anna Wald, a clinical virologist and a professor of medicine at the University of Washington School of Medicine.

There has been little progress on more accurate tests, vaccines or additional treatments over the last few decades, Dr. Wald said. Part of the challenge is that the herpes virus can hide inside neurons that are shielded from the immune system, making the body’s immune response insufficient at eradicating the virus, she said — that’s why herpes remains in a person’s body for life. Vaccine attempts, so far, have not stimulated an immune response that can control the virus or prevent infection, she said.

If a patient does not have symptoms, doctors typically diagnose herpes with an antibody test that is frequently inaccurate. Up to half of positive commercial test results could be false, according to past research . There is another antibody test, called the herpes Western blot, that scientists consider the gold standard in diagnosing herpes — but the test is only available through the University of Washington, which can be cumbersome and expensive for patients to obtain. Testing is typically reliable when a patient has symptoms; doctors can swab a lesion and run a highly sensitive molecular test.

The U.S. Preventive Services Task Force doesn’t recommend routine genital herpes screenings for people without symptoms, in part because false positive rates are so high. On Tuesday, the task force reaffirmed its recommendation . In a related paper , a group of doctors wrote that the recommendation was, in part, based on “psychosocial harms” associated with false positives on herpes tests.

And so the virus continues to spread essentially unchecked — exacerbated by just how ineffective the most widely available tests for herpes are, said Terri Warren, a nurse practitioner who has researched herpes.

As cases circulate, patients are left grappling with a diagnosis that can be psychologically devastating, Dr. Zenilman said.

“You can control the symptoms,” he added. “But lots of people feel stigmatized, dirty.”

How herpes got sidelined

Herpes can be severe in certain cases: Babies can contract neonatal herpes from their mothers, putting them at risk for severe complications and even death . For people who are immunocompromised , outbreaks can be more prolonged and painful. In the vast majority of cases, though, people will have very mild symptoms, and many will have none. That’s part of the reason the infection is so pervasive: People pass it onto partners without knowing they have herpes.

Those who contract HSV-1 may develop blisters on or around their mouths or, in some cases, on their genitals. HSV-2, the other predominant strain, is usually characterized by one or more lesions around the genitals or the rectum. In the United States, around one in six people between the ages of 14 and 49 has genital herpes, and over half of adults have oral herpes.

Antiviral medications help reduce the amount of the virus a person sheds, lowering the chance that someone with herpes will pass it on to a sexual partner. Some patients take antivirals daily; others only take medication when they have an outbreak. But the risk of spreading herpes is never zero. The disease lingers in the body, putting the onus on patients to disclose their diagnosis to anyone with whom they have intimate contact.

When Lauren started dating after her diagnosis, she found herself staying in relationships for longer than she might otherwise, scared nobody else would want to be with her. “I thought I was going to die alone,” she said.

Brittany, 29, who asked that her last name be withheld in order to discuss her personal health, only thinks about her HSV-2 when she scrolls through a dating app. In the two years since she was diagnosed, she’s only had one outbreak. Still, when she looks at each profile, she wonders how the man would respond to learning about her diagnosis. “I just worry so much that people are going to judge me,” she said. “That no matter how I present it to them, I’ll still face rejection. That weighs heavily on me.”

Some men have told her, flat-out, that they would never date someone with herpes, but what bothers her, too, are the ones who say, “I’m so sorry this happened to you.”

“I don’t want people to feel sorry for me,” she said. “I wake up every day and I’m fine.”

Scientists have worked on herpes vaccines in fits and starts since the 1970s, said Dr. Harvey Friedman, a professor of medicine at the University of Pennsylvania Perelman School of Medicine who has studied the disease for over 40 years. But past attempts have failed, for reasons researchers are still trying to uncover.

Because herpes has been around for so long, the viruses have evolved alongside us, making them more difficult to eradicate, said Christine Johnston, an associate professor at the University of Washington School of Medicine who has studied herpes.

There are new vaccines under development . Dr. Friedman is working with BioNTech on an HSV-2 vaccine candidate that was given to the first human subject in December . But none are in late-stage clinical trials, said Dr. Ina Park, a professor of family and community medicine at the University of California, San Francisco, and author of “Strange Bedfellows: Adventures in the Science, History, and Surprising Secrets of S.T.D.s.” “There’s nothing anywhere close to prime time,” she said.

‘One of the biggest secret societies’

When Ella Dawson, 30, contracted genital HSV-1 in college, she started to post openly about her diagnosis on social media. To her surprise, people came out of the woodwork to share their stories — friends, relatives, even a cashier who worked at the grocery store on campus. Many told her that they had never disclosed their diagnosis to anyone other than a sexual partner.

“It’s one of the biggest secret societies in the world,” said Ms. Dawson, a novelist and writer who often speaks publicly about her experience with herpes.

Courtney Brame, 34, started the herpes education advocacy organization and podcast Something Positive for Positive People after his own HSV-2 diagnosis. He’s seen how the disease “completely shatters a person’s identity,” he said, partly because of how central sexuality can be to someone’s self-worth. “They don’t feel like they have anything to contribute to a relationship now, just because they have herpes,” he said. “It’s like, ‘Who’s going to want me now that I have this?’”

Mr. Brame has seen this in his own life. He was once messaging a woman on Tinder who brought up her struggle with chronic asthma; when he disclosed his own chronic condition, she stopped responding. But more often than facing rejection, when he shares his diagnosis, he said, he gets a different response: Women share that they, too, have herpes.

Herpes stigma stems in part from the idea that people with the infection have done something “wrong,” Dr. Park said. But you can exercise every precaution and still get it, she added — condoms do not entirely prevent transmission, and you don’t even need to have penetrative sex to contract the virus.

Though condoms can reduce the risk of transmission, not everyone with herpes will use a barrier method in long-term, monogamous relationships. In 2021, Something Positive for Positive People conducted a survey of over 1,000 people diagnosed with herpes; around 66 percent said a partner had consented to sex without a condom or other barrier method. And there is little research on how the virus spreads between women who have sex with women, Dr. Park said.

Medical providers, in general, often don’t receive extensive education on talking to patients about sexual health, Dr. Johnston said. When it comes to herpes in particular, “health care providers can be really insensitive about it and minimize it,” she said. “This is thought of more as a nuisance than a serious infection.”

“Clinicians don’t want to deal with this,” Ms. Warren said. “It involves people talking about sex. They’re crying, they’re going to have to talk about various specifics like is oral sex OK, is anal sex OK — I don’t think they want to go there,” she said.

Without support from doctors, or medical innovations to cure the infection, people with herpes are left “dealing with two viruses at the same time,” as Ms. Dawson put it. “You’re dealing with the physical symptoms of the virus,” she said, “and you’re dealing with the mental strain.”

Dani Blum is a reporter for Well. More about Dani Blum

Thanks for visiting! GoodRx is not available outside of the United States. If you are trying to access this site from the United States and believe you have received this message in error, please reach out to [email protected] and let us know.

• Alzheimer's & Dementia
• Asthma & Allergies
• Atopic Dermatitis
• Breast Cancer
• Cardiovascular Health
• Environment & Sustainability
• Exercise & Fitness
• Headache & Migraine
• Health Equity
• HIV & AIDS
• Human Biology
• Men's Health
• Mental Health
• Multiple Sclerosis (MS)
• Parkinson's Disease
• Psoriatic Arthritis
• Sexual Health
• Ulcerative Colitis
• Women's Health
• Nutrition & Fitness
• Vitamins & Supplements
• At-Home Testing
• Men’s Health
• Women’s Health
• Latest News
• Medical Myths
• Honest Nutrition
• Through My Eyes
• New Normal Health
• 2023 in medicine
• Why exercise is key to living a long and healthy life
• What do we know about the gut microbiome in IBD?
• My podcast changed me
• Can 'biological race' explain disparities in health?
• Why Parkinson's research is zooming in on the gut
• Health Hubs
• Find a Doctor
• BMI Calculators and Charts
• Blood Pressure Chart: Ranges and Guide
• Breast Cancer: Self-Examination Guide
• Sleep Calculator
• RA Myths vs Facts
• Type 2 Diabetes: Managing Blood Sugar
• Ankylosing Spondylitis Pain: Fact or Fiction
• Our Editorial Process
• Content Integrity
• Conscious Language
• Health Conditions
• Health Products

Is there a cure for herpes? What to know about current research

Herpes is an infection that results from one of two types of herpes simplex virus. Herpes can hide in the nerve cells for a long time before activating, which makes finding a cure challenging. There is currently no cure, but research on vaccines is ongoing.

Most people with herpes do not show symptoms, but the infection can also cause painful ulcers and blisters. Those without symptoms can still pass the infection to others.

Herpes simplex virus 1 (HSV-1) typically causes oral herpes but may also cause genital herpes. People transmit HSV-1 through saliva.

Herpes simplex virus 2 (HSV-2) is a more common cause of genital herpes. A person might acquire HSV-2 through genitalia to genitalia contact, genitalia to mouth contact, or other forms of sexual contact.

This article reviews the reasons there is no cure for herpes, the progress on developing a cure, and the current treatment options.

Is there a herpes cure?

Herpes is a common infection. According to the World Health Organization (WHO) , as of 2016 around half a billion people were living with genital herpes, and several billion had oral herpes.

There is currently no cure or preventive treatment for herpes infection. If a person gets either form of herpes virus infection, they will have it for life, whether or not they experience symptoms.

Researchers have conducted several clinical trials investigating vaccines against herpes infection, but no commercially available vaccine is currently available.

Why creating a cure for herpes is difficult

Herpes is challenging to cure because of the nature of the virus. The HSV virus can hide away in a person’s nerve cells for long periods of time before reappearing and reactivating the virus.

Experts suggest that even if antiviral drugs destroy the active parts of the virus, it only takes a small amount of the virus to hide in the nerve cells and become dormant for the herpes virus to continue persisting in the body.

To find a treatment, scientists need to understand further the mechanism that enables the infection to hide. By learning more about this mechanism, they might be able to develop treatments to target latent HSV and even work toward a function cure.

Current treatment options for herpes

Some medications may reduce the frequency and severity of symptoms and lower the chances of passing the infection on to others. Current antiviral medications to treat herpes include :

• valacyclovir (Valtrex)
• famciclovir (Famvir)

Any of the above medications can be the first form of treatment for HSV infections, depending on the preferences of the healthcare professional and the person with HSV. If a person has a healthy immune system, oral therapy should be an adequate treatment for the virus.

For people with severe infections or compromised immune systems, the doctor may prescribe intravenous (IV) medications to control the infection.

People with high levels of stress or trauma may experience more frequent recurrences of herpes. In this case, a doctor may advise psychotherapy and counseling.

Learn about the best home remedies for herpes.

Prevention of herpes

A person can transmit HSV-1 when they have no symptoms. However, they are most contagious during an outbreak.

People with an HSV-2 infection can transmit genital herpes while experiencing no symptoms. HSV-2 is most contagious during an outbreak of sores.

People should abstain from sexual intercourse while experiencing symptoms. The correct use of condoms and other barrier methods may help to reduce the risk of spreading genital herpes. A person should also avoid oral contact with others or sharing objects that come into contact with saliva. This includes performing oral sex.

Pregnant people with symptoms of genital herpes should speak with a healthcare professional, as there is a risk of neonatal herpes.

Neonatal herpes is where a pregnant person passes the infection on to their fetus before, during, or immediately after delivery. It is rare but can have severe consequences for the infant.

Learn more about herpes and pregnancy.

Research into a cure for herpes

The WHO recognizes the need for further research into preventing and treating HSV.

Clinical trials are underway to search for an effective treatment. A new drug called pritelivir is currently undergoing clinical trials as a treatment for herpes symptoms. Experts believe pritelivir may be a useful alternative for people who cannot take acyclovir.

Scientists are currently studying potential vaccines in their search for a cure for herpes. However, according to a review from 2022 , no HSV vaccine has received FDA approval yet. This is despite eight decades worth of effort to develop a vaccine.

The researchers expressed hope that current developments of the mRNA vaccines due to COVID-19 may help in finding a solution sooner.

Frequently asked questions

The following sections provide answers to frequently asked questions about herpes.

Is herpes contagious forever?

Herpes is a lifelong infection that has periods of flares or outbreaks and remission. A person can pass herpes to their partner at any time, though they have a higher chance when they have an outbreak. Medications can help reduce the risk of spread and reduce the occurrence of flares.

Is there any hope for a cure for herpes?

Medication has come a long way in helping to suppress herpes, and a cure may be possible in the future. According to a 2020 study looking at the effect of adeno-associated virus (AAV)-delivered meganucleases on mice, researchers were able to eliminate 90% of latent virus loads. If translated to humans, it could mean a significant reduction in shedding, lesion severity, and reactivation of the virus.

How do I know if I have herpes?

Symptoms typically appear within 2-12 days of initially having contact with someone who has it on their mouth or genitals. Blisters typically appear at the site where the virus entered the body, crust over after a few days, and then go away.

In some cases, a person may not realize they have it. However, if they experience any symptoms related to herpes, they should ask all of their recent sexual partners if they have or may have oral or genital herpes.

If an infection is possible, a person should consider seeing their doctor for diagnosis and testing.

HSV causes herpes and can affect the mouth or genitals. There is currently no cure for the virus, but treatments exist that can reduce the symptoms and infectiousness of the virus.

Scientists are researching vaccines or compounds that might cure herpes. However, there currently is no vaccine that can help prevent the spread of herpes, so a person should use appropriate protection and precautions when engaging in sexual activity with others.

Last medically reviewed on February 1, 2024

• Public Health
• Immune System / Vaccines
• Infectious Diseases / Bacteria / Viruses
• Sexual Health / STDs

How we reviewed this article:

• Aubert M, et al. (2020). Gene editing and elimination of latent herpes simplex virus in vivo. https://www.nature.com/articles/s41467-020-17936-5
• Awasthi S, et al. (2022). An mRNA vaccine to prevent genital herpes. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8695322/
• Billions worldwide living with herpes. (2020). https://www.who.int/news-room/detail/01-05-2020-billions-worldwide-living-with-herpes
• Cohen J I, et al. (2020). Herpesvirus latency. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7324166
• Genital herpes. (2023). https://www.womenshealth.gov/a-z-topics/genital-herpes
• Genital herpes – Cdc basic fact sheet. (2022). https://www.cdc.gov/std/herpes/stdfact-herpes.htm
• Genital herpes: Overview. (2018). https://www.ncbi.nlm.nih.gov/books/NBK525769/
• Herpes simplex virus. (2023). https://www.who.int/news-room/fact-sheets/detail/herpes-simplex-virus
• Krishnan R, et al. (2021), Developments in vaccination for herpes simplex virus. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8691362
• Ramgopal S, et al. (2020). Diagnosis and management of neonatal herpes simplex infection in the emergency department. https://journals.lww.com/pec-online/Abstract/2020/04000/Diagnosis_and_Management_of_Neonatal_Herpes.7.aspx
• Sauerbrei A. (2016). Herpes genitalis: Diagnosis, treatment and prevention. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5177552/
• Tajpara P, et al. (2019). A preclinical model for studying herpes simplex virus infection. https://www.sciencedirect.com/science/article/pii/S0022202X18327945
• Treatment for genital herpes. (n.d.). https://www.ashasexualhealth.org/herpes-treatment/

Share this article

Latest news

Related coverage.

Herpes simplex is a very common virus that affects billions of people globally. It can cause sores around the mouth or on the genitals and surrounding…

People may notice herpes symptoms across the body, including in the mouth, on the genitals, or in the eyes. Learn more here.

Herpes skin rash outbreaks usually affect the mouth or genitals, but they can appear anywhere on the body. Learn more about herpes skin rashes here.

Epstein-Barr virus is very common. Most people who contract the virus do not develop symptoms, but others get mononucleosis or other conditions.

Disclosing a herpes diagnosis can be challenging. Learn more about how to do this and when to disclose this information here.

NIH Releases Strategic Plan for Research on Herpes Simplex Virus 1 and 2

Plan will advance understanding of herpes virology and accelerate development of diagnostics, vaccines, and therapies.

September 19, 2023

NIH’s approach to HSV research

In response to the persistent health challenges of herpes simplex virus 1 (HSV-1) and HSV-2, today the National Institutes of Health released the Strategic Plan for Herpes Simplex Virus Research . An NIH-wide HSV Working Group developed the plan, informed by feedback from more than 100 representatives of the research and advocacy communities and interested public stakeholders. The plan outlines an HSV research framework with four strategic priorities: improving fundamental knowledge of HSV biology, pathogenesis, and epidemiology; accelerating research to improve HSV diagnosis; improving strategies to treat HSV while seeking a curative therapeutic; and, advancing research to prevent HSV infection.

HSV-1 and HSV-2 are among the most common viral infections in the United States. HSV can cause recurring blisters or sores. In severe cases HSV may lead to life-threatening or long-term complications, typically in the central nervous system. There are no licensed preventive HSV vaccines, and there is no cure. Up to 80% of people between the ages of 14 and 49 years in the United States live with HSV-1, and more than 10% live with HSV-2. HSV symptoms are primarily managed with antivirals that can reduce their frequency and intensity, but those medications do not clear the infection. Asymptomatic HSV is extremely common, and people who are asymptomatic can still transmit HSV to others. HSV is a leading cause of viral encephalitis—brain inflammation from a viral infection—and infectious blindness worldwide. Neonatal herpes, if left untreated, is fatal in 60% of cases. 

The NIH HSV Working Group was established in October 2022 and consists of scientific and policy experts from the National Institute of Allergy and Infectious Diseases, the National Institute on Mental Health, the National Institute on Neurological Disorders and Stroke, the National Institute on Aging, the National Institute on Minority Health and Health Disparities, the Eunice Kennedy Shriver National Institute on Child Health and Human Development, and the National Eye Institute. This plan aligns with ongoing national efforts, including the Sexually Transmitted Infections National Strategic Plan , and reflects broad public input, including individual experiences with HSV care, as well as the mental health impact of HSV social stigma. NIH anticipates that this plan will serve as a foundation for research, public health and medical communities to collaboratively work to reduce the burden of HSV-1 and HSV-2. 

WHAT: NIH Strategic Plan for Herpes Simplex Virus Research 

WHO: Carolyn Deal, Ph.D., chief of the Enteric and Sexually Transmitted Infections Branch in NIAID’s Division of Microbiology and Infectious Diseases, is available to comment on the significance and implementation of the plan.

Submit a Media Request

Contact the NIAID News & Science Writing Branch.

301-402-1663 [email protected] All Media Contacts

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

• View all journals

Herpes virus articles from across Nature Portfolio

Herpesvirus is an infectious agent belonging to the virus family Herpesviridae that causes latent and lytic infections in a wide range of animals and humans. There are 8 herpesvirus types currently known to infect humans, including Herpes simplex viruses, varicella-zoster virus, Epstein-Barr virus, Kaposi's sarcoma-associated herpesvirus and human cytomegalovirus.

Latest Research and Reviews

Neuronal miR-9 promotes HSV-1 epigenetic silencing and latency by repressing Oct-1 and Onecut family genes

Here, the authors identify neuron-specific miR-9 that potentially blocks HSV-1 neuronal replication by targeting host OCT-1 and ONECUT transcription factors involved in epigenetic activation of HSV-1 productive-cycle genes. Thus miR-9 promotes viral epigenetic silencing and latent infection in neurons.

Human cytomegalovirus exploits STING signaling and counteracts IFN/ISG induction to facilitate infection of dendritic cells

Human cytomegalovirus (HCMV) is a ubiquitous pathogen associated with morbidity and mortality in the immunocompromised or immunonaive context. Here the authors show that HCMV exploits STING signalling and subverts the interferon response to support infection of monocyte derive dendritic cells.

• Bibiana Costa
• Jennifer Becker
• Ulrich Kalinke

Multivalent cytomegalovirus glycoprotein B nucleoside modified mRNA vaccines did not demonstrate a greater antibody breadth

• Hsuan-Yuan Wang
• Sallie R. Permar

Hijacking of nucleotide biosynthesis and deamidation-mediated glycolysis by an oncogenic herpesvirus

The oncogenic Kaposi’s sarcoma-associated herpesvirus (KSHV) is known to reprogram cellular metabolism. Here, Wan et al show that viral Cyclin exploits host nucleotide synthesis and glycolysis to support KSHV pathogenesis.

• Quanyuan Wan
• Leah Tavakoli

A cytomegalovirus inflammasome inhibitor reduces proinflammatory cytokine release and pyroptosis

Viruses have evolved specific mechanisms to reduce programmed cell death in order to prolong survival. Here the authors show a mouse cytomegalovirus (MCMV) encoded protein that inhibits pyroptosis, proinflammatory cytokine release and the assembly of inflammasomes.

• Yingqi Deng
• Eleonore Ostermann
• Wolfram Brune

HHV-6B detection and host gene expression implicate HHV-6B as pulmonary pathogen after hematopoietic cell transplant

Lower respiratory tract disease is a common complication after allogeneic hematopoietic cell transplant (HCT), but underlying reasons remain unclear. Here the authors show that HHV-6B detection in the lungs of allogeneic HCT recipients is associated with increased risk for death and distinct host gene expression profiles, implicating HHV-6B as a pulmonary pathogen in these patients.

• Joshua A. Hill
• Yeon Joo Lee
• Michael Boeckh

News and Comment

EBV linked to multiple sclerosis

Two recent papers implicate Epstein–Barr virus (EBV) as a trigger for the development of multiple sclerosis and provide mechanistic insights into EBV-mediated development of the disease.

• Andrea Du Toit

Motor-powered trafficking

This study provides insights into the neuroinvasive mechanism of neurotropic alphaherpesviruses, which involves viral assimilation and repurposing of a cellular motor protein.

Making the cut

This study reports the development of a CRISPR –Cas9 therapeutic to target herpes simplex virus 1 and treat herpetic stromal keratitis in mice.

Controlling the nucleus from a distance

This paper found that cytoplasmic control of intranuclear polarity by human cytomegalovirus leads to segregation of viral DNA from heterochromatin, thus promoting virus replication.

• Ashley York

Exploiting peroxisomes

New activities for old antibiotics

Topical administration of aminoglycoside antibiotics has been shown to induce expression of interferon-stimulated genes in dendritic cells, inducing an antiviral state in the vaginal and lung mucosa that increases resistance to infection with herpes simplex virus 1, influenza and Zika viruses.

• Jeffrey I. Cohen

Quick links

• Explore articles by subject
• Guide to authors
• Editorial policies

• History, Facts & Figures
• YSM Dean & Deputy Deans
• YSM Administration
• Department Chairs
• YSM Executive Group
• YSM Board of Permanent Officers
• FAC Documents
• Current FAC Members
• Appointments & Promotions Committees
• Ad Hoc Committees and Working Groups
• Chair Searches
• Leadership Searches
• Organization Charts
• Faculty Demographic Data
• Professionalism Reporting Data
• 2022 Diversity Engagement Survey
• State of the School Archive
• Faculty Climate Survey: YSM Results
• Strategic Planning
• Mission Statement & Process
• Beyond Sterling Hall
• COVID-19 Series Workshops
• Previous Workshops
• Departments & Centers
• Find People
• Biomedical Data Science
• Health Equity
• Inflammation
• Neuroscience
• Global Health
• Diabetes and Metabolism
• Policies & Procedures
• Media Relations
• A to Z YSM Lab Websites
• A-Z Faculty List
• A-Z Staff List
• A to Z Abbreviations
• Dept. Diversity Vice Chairs & Champions
• Dean’s Advisory Council on Lesbian, Gay, Bisexual, Transgender, Queer and Intersex Affairs Website
• Minority Organization for Retention and Expansion Website
• Office for Women in Medicine and Science
• Committee on the Status of Women in Medicine Website
• Director of Scientist Diversity and Inclusion
• Diversity Supplements
• Frequently Asked Questions
• Recruitment
• By Department & Program
• News & Events
• Executive Committee
• Aperture: Women in Medicine
• Self-Reflection
• Portraits of Strength
• Mindful: Mental Health Through Art
• Event Photo Galleries
• Additional Support
• MD-PhD Program
• PA Online Program
• Joint MD Programs
• How to Apply
• Advanced Health Sciences Research
• Clinical Informatics & Data Science
• Clinical Investigation
• Medical Education
• Visiting Student Programs
• Special Programs & Student Opportunities
• Residency & Fellowship Programs
• Center for Med Ed
• Organizational Chart
• Academic/Professional Development
• First Fridays
• Fund for Physician-Scientist Mentorship
• Grant Library
• Grant Writing Course
• Mock Study Section
• Research Paper Writing
• Funding Opportunities
• Join Our Voluntary Faculty
• Research by Keyword
• Research by Department
• Research by Global Location
• Translational Research
• Research Cores & Services
• Program for the Promotion of Interdisciplinary Team Science (POINTS)
• CEnR Steering Committee
• Experiential Learning Subcommittee
• Goals & Objectives
• Embryonic Stem Cell Research Oversight
• COVID-19 Vaccinations in CT
• COVID-19 in Connecticut Schools
• Connecticut Towns COVID-19 Impact Dashboard
• Connecticut Town 14-Day Cases Time Lapse
• CT Correctional Facilities with COVID Cases Dashboard
• Connecticut COVID Presence Map
• CT Nursing Homes with COVID-19 Cases
• U.S. COVID Presence Map
• COVID-19 Case Density by US County
• Global Cases Dashboard
• Time-Lapse of Global Spread
• US Racial and Ethnic Disparities in COVID-19 Mortality
• Childcare Survey and Data Display
• Risk of Complications Conditional on COVID-19 Infection
• Travel Time to COVID Testing Sites in Connecticut
• Travel Time to COVID Testing Sites in the US
• Project Team
• Issues List
• Print Magazine PDFs
• Print Newsletter PDFs
• YSM Events Newsletter
• Social Media
• Patient Care

INFORMATION FOR

• Residents & Fellows
• Researchers

How the Stigma of Herpes Harms Patients and Stymies Research for a Cure

“Well, my life is over,” Christopher Pickering remembers thinking.

It was the height of the COVID-19 pandemic when he first noticed the painful urination, swollen lymph nodes, over 20 blisters in his pubic area, and a dull, aching, burning pain. “This isn’t anything, it’s just a friction burn,” he assured himself, trying to suppress his gut feeling on what the blisters actually meant. “I can’t be the kind of person who gets [herpes].” Because COVID had shut down all the sexual health clinics in Toronto, he found himself wandering into a busy walk-in clinic. The doctor confirmed his symptoms were likely herpes , swabbed one of the blisters, and quickly sent him away with a prescription to help him get through his first outbreak.

On the bus ride home, antivirals in hand, Pickering processed his new reality. Now a patient advocate on TikTok , he speaks openly to his over 100,000 followers about his diagnosis and journey to acceptance. But in that moment, he thought, “no one is going to accept me.”

Herpes simplex virus 1 and 2 [HSV-1 and HSV-2] infections are exceedingly common. As many as half to 60 percent of adults in United States have oral herpes, caused by HSV-1, and one of six individuals lives with genital herpes, caused by either HSV-1 or HSV-2. Despite this, the effects of the stigmatization of herpes are pervasive. Upon diagnosis, many patients have found that their providers aren’t well-informed about the condition, which got wide public attention in the 1970s and 80s that receded when deadly HIV/AIDS took hold.

The attention faded, but the virus didn’t. Patients who are infected often go on to experience severe mental health impacts in addition to the physical symptoms, but fear of stigmatization keeps many from advocating for themselves. Furthermore, the lack of funding can stymie research that could be life-changing for the millions living with the condition. As the COVID-19 pandemic and prevalence of long COVID highlight the urgent need to better understand the long-lasting impacts of viral infections, researchers and patients alike hope it will also generate interest in other chronic viral illnesses like herpes.

“Herpes can be a devastating disease. But because it’s sexually transmitted, people don’t want to talk about it,” says Akiko Iwasaki, PhD , Sterling Professor of Immunobiology and professor of dermatology; of molecular, cellular & developmental biology; and of epidemiology (microbial diseases). In her lab at Yale School of Medicine, Iwasaki has developed a therapeutic vaccine that can successfully shut down the reactivation of genital herpes in guinea pigs, but lack of investment has hindered it from progressing to human trials. “People used to email me all the time asking when a vaccine would be available, saying their lives had been destroyed by the virus. But without interest from pharmaceutical companies, we can’t go any farther.”

The Psychosocial Impact of Genital Herpes

Sexually transmitted infections are surging nationwide. Between 2017 and 2021, the Centers for Disease Control and Prevention (CDC) reported that cases of gonorrhea increased by 28 percent, and syphilis by 74 percent. Less testing and education during the height of the COVID-19 pandemic, says Dana Dunne, MD, MHS , associate professor of medicine (infectious diseases), contributed largely to this surge. “Our ability to test and treat sexually transmitted infections really shut down between 2020 and 2021,” she says. “So now that we’re able to test more frequently again, we’re seeing a lot more cases because of the ongoing, unchecked transmission when we were unable to intervene.”

However, the 2021 report has a notable omission—herpes. Due to its difficulty to track and a lack of accurate testing, the CDC doesn’t recommend that the infection be included in standard sexually transmitted infection  panels. But chronic viral infection, especially HSV-2, can significantly impact a patient’s quality of life.

People used to email me all the time asking when a vaccine would be available, saying their lives had been destroyed by the virus. But without interest from pharmaceutical companies, we can’t go any farther. Akiko Iwasaki, PhD

When people acquire herpes, the virus stays mostly asleep in the body for the rest of their lives, emerging just from time to time. Most people living with herpes—as many as 90 percent of them—either are asymptomatic or have symptoms so subtle they don’t realize they are infected. In symptomatic cases, HSV-1 is associated with cold sores, and while it can be transmitted through kissing, it also can be passed through more informal kinds of contact such as sharing cups. HSV-2, on the other hand, causes genital sores and is typically acquired through sexual contact. However, both HSV-1 and HSV-2 can cross anatomic sites—individuals can get HSV-1 on their genitals, and more rarely, HSV-2 in their mouths.

Despite their similarities, HSV-1 and HSV-2 have vastly different psychosocial implications, says Dunne. While there isn’t much perceived stigma around getting a cold sore, she explains, people with HSV-2 often face fear and uncertainty about how to disclose their status to their partners. “They feel like they’re branded with a letter H on their forehead,” she says. This can make patients reluctant to get tested for it and physicians conflicted on when to test.

“The most significant challenge of living with herpes by far—and I don’t think this is covered anywhere close to what it should be in the media and scientific community—is the psychological impact,” says Brandon [name changed for privacy], a 42-year-old attorney, who has put off re-entering the dating pool after his recent divorce. “I can’t for the life of me put any energy into dating anymore because I just don’t know how to tell people about this diagnosis.”

“Living with herpes feels like a prison sentence,” says Natalie [name also changed], a nurse practitioner who sat on an ice pack during her interview to cope with the pain of one of her outbreaks, which are frequent despite taking antivirals. “You’ll have these wonderful periods of time where you have no outbreaks, but you still have this dread knowing it will come back. It’s devastating.”

Lack of Education and Effective Herpes Testing Are Barriers to Patients

Furthermore, many patients say that a lack of accurate testing and ignorance about the condition among their providers pose further challenges. There are two ways to test for the virus. For a patient with an active outbreak, clinicians can directly swab the sore and provide a highly accurate result. Asymptomatic patients can seek out a blood test, but there is significant risk of receiving a false positive. “Current testing measures are absolutely not adequate. We’ve had the same tests on the market for decades,” says Jeffrey Klausner, MD , professor of clinical population and public health sciences at Keck School of Medicine of the University of Southern California. “There just hasn’t been a push or demand for expansion of confirmatory testing.”

“I believe a lot of doctors avoid using the blood test because they don’t know how to counsel patients if it’s positive,” Dunne adds. “Physicians need to know how to counsel patients, as well as be familiar with how to recognize a true positive and false positive and how to troubleshoot the tests that are inconclusive.”

Fourteen years ago, Natalie went to two different clinics, where her symptoms were dismissed as a urinary tract infection or yeast infection. Although she was not yet a nurse practitioner, she regrets not demanding further testing, a decision that haunts her to this day. She ended up transmitting the virus to her now-husband, who was diagnosed immediately after his symptoms appeared. “I live with the shame that I am a victim and also that I became a spreader,” she says. “My husband says I am his dream woman, but that I am also his nightmare because of what I did.”

When Brandon was diagnosed after noticing a pimple-like sore on his groin ten days after protected intercourse with a new partner, he asked an internal medicine physician about how to disclose it. The doctor told him that if he didn’t have active outbreaks, he had nothing to worry about. “Conflicting advice by doctors has put a huge psychological burden on me,” he says.

The root of the widespread ignorance among providers, says Klausner, begins in part during medical school. For about 10 years, he taught a course on sexually transmitted infections at the University of California, Los Angeles, School of Medicine, where he had about 55 minutes to cover over a dozen different infections. “We don’t provide enough opportunity for education and training around sexual health in medical school,” he says. “Our society has always had a difficult time talking about sexual health, and as a result so many medical professionals are poorly trained in how to listen to and counsel patients.”

Lack of Funding Hinders Herpes Vaccine Research

For decades, scientists have tried and failed to develop vaccines for herpes. The evasive nature of the virus makes it notoriously difficult to treat. But in her lab at Yale, Iwasaki has discovered promising clues for an effective vaccination.

Conventional vaccines boost immunity by triggering antibody development. But after vaccinating mice for HSV-2 with conventional vaccines, Iwasaki’s team learned that the animals failed to develop T cells or antibodies in the genital tract. In addition, the virus displays molecules that inactivate antibodies from attacking the virus. The limited access of T cells and antibodies to the viral entry site, and the antibody evasion strategies, likely explain why previous herpes vaccines have failed.

Based on that insight, roughly a decade ago the team developed a vaccine strategy called “prime-and-pull.” Through this mechanism, the researchers used a vaccine to generate T cell immunity in guinea pigs [prime]. Then, they used a cream that can induce chemokines—signaling molecules that can direct immune cells toward an infected site—to attract the T cells into the vaginal tissue [pull].

The strategy was a success —the team found that their vaccine could shut down the reactivation of herpes in infected guinea pigs. But the lack of funding has brought their work to a halt. “We’re looking for partners to be able to take this to humans, and that’s been the bottleneck ever since,” Iwasaki says.

She believes the stigma around sexually transmitted diseases is likely one of the obstacles to getting her vaccine funded. Research shows that the human papillomavirus  (HPV) vaccine Gardasil, for example, is dramatically effective in preventing cervical cancer—reducing rates in women by nearly 90 percent. But despite its benefits, convincing parents to vaccinate their children is challenging, experts say.

“We have this fabulous anti-cancer vaccine designed to wipe out cervical cancer. But parents will see that it is ‘an STD vaccine’ and think we’re accusing their son or daughter of being high-risk sexually,” says Sten Vermund, MD, PhD , Anna M.R. Lauder Professor of Public Health. “I tell them that HPV is so ubiquitous and easy to contract that most women will acquire it at some point in their life. It’s not a marker of unsafe sex, but many parents still refuse.”

A herpes vaccine may face similar resistance, making it economically unattractive for the drug industry. “When pharmaceutical companies need to pour millions of dollars into developing a vaccine, if the uptake is going to be low, the profit doesn’t justify the effort,” says Iwasaki. “This makes STD vaccines difficult, even for something so obviously beneficial, safe, and effective as Gardasil.”

As interest in mRNA vaccines grows post-COVID, Moderna and Pfizer have begun working on such a vaccine for herpes. But in a recent talk to the World Health Organization (WHO), Iwasaki warned of the limitations of mRNA vaccines in treating herpes. “If you just make a vaccine without thinking about the mucosal tissue, it’s not going to work,” she said. “Just making an intra-muscular vaccine alone—I think it will be very difficult for such a vaccine to be effective.”

Advocates for Herpes Patients Rise Above the Stigma

The COVID-19 pandemic has shed light on the highly pervasive nature of viruses. As hundreds of millions of individuals recover from a SARS-CoV-2 infection, as many as one in eight experience lingering physical, cognitive, and neurological symptoms known as long COVID. While post-viral syndromes are not new, they have long been ignored by researchers. However, the magnitude of “long haulers” became too large for the medical community to sweep under the rug.

Many viral infections have been linked to autoimmune and neurological disease. For instance, research suggests that the Epstein-Barr virus (EBV), a member of the herpes virus family that is known for causing mononucleosis, may play a role in triggering multiple sclerosis. Individuals infected with EBV are 32 times more likely to develop the disease. Research has also uncovered potential links between HSV-1 and Alzheimer’s disease—the virus has been linked to amyloid plaque-like formations in human brain-like tissue. More research will be needed to see if herpes is causing the neurodegenerative disease, says Iwasaki. But this will require more investment in studying the infection.

As patients with long COVID struggle to find answers, many have rallied to advocate awareness about the need for more research. But patients with herpes face a much greater stigma that leaves many fearful to speak up about the need for new treatments. Now, as the medical community shows a growing interest in poorly understood viruses, patients are beginning to take a stand. In 2020, Herpes Cure Advocacy , the first grassroots international advocacy organization for HSV-1 and HSV-2, was born. The organization is advocating for the National Institutes of Health (NIH) to invest more in therapeutic cure research and for the CDC to establish an HSV taskforce. “Our job is to raise awareness, try to share medically accurate information, and hold public health agencies accountable to try to change the field the best we can,” says Kimberley, a patient advocate who founded the organization. For privacy, she has asked that her last name not be included.

For Pickering, who continues to make videos about herpes on TikTok and other social media platforms, learning to question the stigma about herpes helped him become less afraid of it. “People are not judging you if you don’t judge yourself,” he says in his recent YouTube video . “The stigma might never go away in the heads of everyone else and in society, but you can realize what the stigma is about, that you don’t have to hold onto it, and that you don’t have to be impacted by someone’s harsh words because those harsh words don’t make any sense.”

And advocacy efforts are beginning to pay off. For instance, prodded by Herpes Cure Advocacy, the Office of the Assistant Secretary for Health is working on the first national strategy for the cure, treatment, and prevention of herpes.

“Public health officials have a lot of competing priorities, so if we want change, we need more voices,” says Klausner. “If we want a cure and vaccines for herpes, we need to scream and yell for them.”

Featured in this article

• Akiko Iwasaki, PhD Sterling Professor of Immunobiology and Professor of Dermatology and of Molecular, Cellular, and Developmental Biology and of Epidemiology (Microbial Diseases); Investigator, Howard Hughes Medical Institute
• Dana Dunne, MD, MHS Associate Professor of Medicine (Infectious Diseases); Associate DIO; GME Director, Educator Development, Department of Medicine; Associate, Teaching and Learning Center; Associate Chair for Education and Academic Affairs, Internal Medicine; Director of YMS Coaching Program , Office of Curriculum
• Sten H. Vermund, MD, PhD Anna M.R. Lauder Professor of Public Health

Search Icon

Events See all →

April wellness walk.

The Division of Human Resources and the Penn Center for Public Health host the monthly two-mile wellness walk for April, which is the first outdoor walk of the year. 

12:00 p.m. - 1:00 p.m.

College Hall, Benjamin Franklin Statue

Immigration Policy and the Election

1:00 p.m. - 6:30 p.m.

The Perelman Center for Political Science and Economics, 133 S. 36th St.

2024 Models of Excellence

4:00 p.m. - 6:30 p.m.

Penn Museum, 3260 South St.

Take Our Children to Work Day

Various locations

Health Sciences

A new herpes vaccine leaves no trace of infection or disease

A novel vaccine developed at penn medicine protected almost all animal subjects exposed to the virus..

Researchers from the Perelman School of Medicine have developed a vaccine to protect against genital herpes. Tested on both mice and guinea pigs, the immunization led to “mostly sterilizing immunity” from the virus—the strongest type of immunity. The results of the study are published in  Science Immunology .

In the study, researchers delivered the Penn-developed vaccine to 64 mice and then exposed them to genital herpes. After 28 days, 63 of the mice were found to have sterilizing immunity, meaning there was no trace of herpes infection or disease after the exposure. The one remaining mouse developed dormant infection without any prior genital disease. Similarly, 10 guinea pigs, which have responses to herpes infections that more closely resemble that of humans, were also given the vaccine and exposed to the virus. No animal developed genital lesions and only two showed any evidence that they became infected, but the infection was not in a form that animals could transmit the virus.

“We’re extremely encouraged by the substantial immunizing effect our vaccine had in these animal models,” says the study’s principal investigator  Harvey Friedman, a professor of infectious diseases. “Based on these results, it is our hope that this vaccine could be translated into human studies to test both the safety and efficacy of our approach.”

Read more at Penn Medicine News.

Penn celebrates operation and benefits of largest solar power project in Pennsylvania

Arts, Humanities, & Social Sciences

‘The Illuminated Body’ fuses color, light, and sound

A new Arthur Ross Gallery exhibition of work by artist Barbara Earl Thomas features cut-paper portraits reminiscent of stained glass and an immersive installation constructed with intricately cut material lit from behind.

Campus & Community

25 years of ‘LOVE’

The iconic sculpture by pop artist Robert Indiana arrived on campus in 1999 and soon became a natural place to come together.

Two-and-a-half decades of research in Malawi

As the country’s life expectancy has risen, the Malawi Longitudinal Study of Families and Health has shifted its current and future research to aging.

Science & Technology

In hot water: Coral resilience in the face of climate change

Over a decade, researchers from Penn studied coral species in Hawaii to better understand their adaptability to the effects of climate change.

Western News

By 2030, the World Health Organization (WHO), the Global Fund and UNAIDS are hoping to end the human immunodeficiency virus (HIV) and AIDS epidemic. An international team of researchers led by Eric Arts, professor at the Schulich School of Medicine & Dentistry , and Jamie Mann, senior lecturer at the University of Bristol (U.K.), has brought us another step closer to meeting this goal, by finding an effective and affordable targeted treatment strategy for an HIV cure.  

In a first, the study published in the journal Emerging Microbes and Infections demonstrated the team’s patented therapeutic candidate, an HIV-virus-like-particle (HLP), is 100 times more effective than other candidate HIV cure therapeutics for people living with chronic HIV on combined antiretroviral therapy (cART). If successful in clinical trials, HLP could be used by millions of people living around the world to free them of HIV. This study was done using blood samples from people living with chronic HIV.  

HLPs are dead HIV particles hosting a comprehensive set of HIV proteins that increase immune responses without infecting a person. When compared with other potential cure approaches, HLP is an affordable biotherapeutic and can be administered by intramuscular injection – similar to the seasonal flu vaccine.  

“The development of this HIV cure was ten years in the making but with strong support from our collaborators in the U.S., Canada and Uganda, we have observed a striking ability of HLP to drive out the last remnants of HIV-1, which we hope will provide an affordable cure for all,” said Arts, who is a Canada Research Chair in HIV Pathogenesis and Viral Control. “To live HIV-free is a goal for the 39 million infected. It is also the priority of the UN and WHO to end the HIV pandemic by 2030.”  

HIV is a retrovirus that attacks the body’s immune system and if left untreated, can lead to acquired immunodeficiency syndrome (AIDS). The virus weakens a person’s immune system by destroying CD4-T white blood cells, which are tasked with helping the immune system fight infections. Approximately 95 per cent of people living with HIV have chronic HIV – where the virus is slowly causing a slow destruction of the patients’ immune systems when they initiated lifelong cART.

Larger global studies planned in future  

Postdoctoral scholar Minh Ha Ngo (Megan Morris/Schulich School of Medicine & Dentistry photo)

While cART is effective at treating HIV, it has been unable to completely eliminate the virus from the body. This is because of the virus’ ability to create a “latent reservoir” – where it hides dormant inside of cells, safe from detection. Using blood samples from 32 participants living with chronic HIV from the U.S., Uganda and Canada, who were on stable cART for a median of approximately 13 years, researchers found that HLP was able to specifically target just the immune cells containing latent HIV reservoir and purge these cells of their HIV, a critical step towards an HIV-1 cure. An HIV cure is typically described as therapy and approach that eliminates all HIV without the need of continuous antiretroviral therapy.  

“ Over time, the virus grows more diverse within a single individual that is not on treatment which makes it more difficult to target, ” said co-lead author Ryan Ho, master’s student in the department of microbiology and immunology. “This formulation we’ve crafted covers the theoretical diversity so it can reach the HIV-1 in all those people living with HIV.”  

Minh Ha Ngo, lead author and postdoctoral scholar in the department of microbiology and immunology, says one concern expressed among people living with HIV for years is that continued use of cART could lead to the virus becoming unreachable and unable to be eliminated. The results of this study, by contrast, demonstrate that combining HLP with cART is still able to trigger the latent reservoir, even in chronic cases. If these dormant latent reservoirs can be awakened, then they can be eliminated from the body.   

Jamie Mann, senior lecturer at the University of Bristol (Jamie Mann photo)

“Owing to its high mutation rate, HIV exhibits remarkable genetic diversity, resulting in different viral subtypes; some of which predominate in particular regions of the globe,” said Mann. “We were excited to see preliminary evidence that our HLP cure therapy reverses latency irrespective of the subtype of the individual’s infection. Whilst this needs to be explored further, it hints at the global applicability of our approach.”  

In the future, researchers plan to test HLP on a larger representative HIV cohort with subtype C infections, which includes people living in South Africa, Ethiopia, Vietnam and India. This would help determine if the treatment strategy is effective for most people living with acute and chronic HIV.  

Current studies involve confirming a lack of toxicity in preparation for human clinical trials.  

These studies will be made possible with the advanced Pathogen Research Centre at Schulich Medicine & Dentistry. This study was conducted in collaboration with University of Bristol, University of Toronto, Case Western Reserve University, Rakai Health Sciences Program, Johns Hopkins University School of Medicine and the U.S. National Institutes of Health.  

The study was funded by the American Foundation for AIDS Research, and by the Canadian Institutes of Health Research, U.S. National Institute of Allergy and Infectious Diseases; part of the National Institutes of Health, and the Canada Research Chairs Program.  

Topic Headline 3 Research

SHARE THIS STORY

Up next ….

Bioethicist Maxwell Smith named first Chair in Applied Public Health at Western

Headline 1 , Research

Leader in public health ethics receives national honour

Related Stories

Popular this week.

• Researchers a step closer to HIV cure 527 views
• Geoffrey Little named new vice-provost and chief librarian 385 views
• Western innovators receive Early Researcher Awards 286 views

What to know about perimenopause after Halle Berry says she was misdiagnosed

The 57-year-old actress shared her story with first lady Jill Biden.

Halle Berry is opening up about a misdiagnosis several years ago that led to her realizing she was experiencing perimenopause .

Berry, now 57, said a doctor told her three years ago that she had an extremely bad case of herpes after she sought treatment for extreme pain after sex.

Both she and her partner subsequently tested negative for herpes, according to Berry, who said she then learned that vaginal dryness, which led to the misdiagnosis, is a symptom of perimenopause, the time when a woman's ovaries gradually begin to make less estrogen.

"My doctor had no knowledge and didn't prepare me," Berry said Monday in a conversation with first lady Jill Biden at the Day of Unreasonable Conversation summit in Los Angeles, according to The Hollywood Reporter , the event's media partner.

Berry, a mom of two, said the experience motivated her to speak out about perimenopause and menopause in order to help break the stigma of the two women's health conditions.

"That's when I knew, 'Oh my gosh, I've got to use my platform,'" Berry said. "I have to use all of who I am and I have to start making a change and a difference for other women.'"

Berry's conversation with the first lady came just over one week after President Joe Biden signed an executive order on women's health research, which particularly focuses on increasing research on women's midlife health and improving management of menopause-related issues.

MORE: New book busts myths, answers common questions about menopause

Menopause and other women-only health conditions have traditionally lagged behind in research and understanding. As recently as the 1970s, few women were enrolled in clinical trials , and women's health needs were believed to be a low priority. One 2022 study found women still account for only between 29% and 34% of early-stage clinical trials due to concerns about fertility.

Editor’s Picks

Wynonna Judd gets real about menopause: 'I’m not going to be ashamed'

What women should know about their reproductive system as they age

FDA approves first-of-its-kind drug to treat hot flashes

Berry said Monday she is using her platform to change the stigma around women as they age and wants others to do so as well, saying, "Help us change the way culture views women at this stage of our lives."

Signs and symptoms of perimenopause, menopause

Perimenopause is the period of time before menopause when ovaries gradually begin to make less estrogen. Perimenopause can start as early as 40 years old and can last up to 10 or more years, according to ABC News chief medical correspondent Dr. Jennifer Ashton, a board-certified OBGYN and obesity medicine physician.

For most women, the period of menopause lasts four years, according to the U.S. Office on Women's Health .

Symptoms of perimenopause include everything from changes in mood to increased anxiety and depression, changes in sleep, brain fogginess and changes in frequency and severity of headaches, according to Ashton.

On the physical side, Ashton said other symptoms of perimenopause can include changes in hair patterns, breast tenderness, midsection weight gain, vaginal dryness, changes in bleeding patterns and changes in libido.

"None of those are symptoms that you want to ignore," said Ashton. "You want to just keep track of what's going on with you and then discuss it with your gynecologist."

MORE: I went through menopause before I turned 40 and this is what I want women to know

Women can still get pregnant during perimenopause as the body may still ovulate.

A woman is officially in menopause when she has not had any menstruation, including no bleeding or spotting, for a full year, according to the Office on Women's Health.

The average age for menopause in the U.S. is 52, but a woman may experience it earlier if they have never been pregnant, if they smoke, or if they have certain health conditions , including some autoimmune diseases.

After menopause, women may continue to experience symptoms including vaginal dryness, hot flashes and low hormone levels, according to the Office on Women's Health .

There are ways to treat symptoms of menopause so women are advised to have open and honest conversations with their doctor to get relief.

ABC News' Mary Kekatos contributed to this report.

Top Stories

Prosecutors say Trump team trying to 'rewrite indictment' in bid to toss Georgia case

• 22 minutes ago

Bridge collapse live updates: First responders called out to people on bridge

• 29 minutes ago

Democrats sound alarm on RFK Jr. and new running mate, Shanahan

• Mar 27, 3:34 PM

RNC won't pay Trump's bills, daughter-in-law says, insisting 2020 is 'in the past'

• Mar 27, 3:27 PM

'Fourth Wing' author Rebecca Yarros announces title of 3rd book in Empyrean series

• 4 hours ago

ABC News Live

24/7 coverage of breaking news and live events

Researchers a step closer to a cure for HIV

By 2030, the World Health Organization (WHO), the Global Fund and UNAIDS are hoping to end the human immunodeficiency virus (HIV) and AIDS epidemic. An international team of researchers led by Eric Arts, professor at the Schulich School of Medicine & Dentistry, and Jamie Mann, senior lecturer at the University of Bristol (U.K.), has brought us another step closer to meeting this goal, by finding an effective and affordable targeted treatment strategy for an HIV cure.

In a first, the study published in the journal Emerging Microbes and Infections demonstrated the team's patented therapeutic candidate, an HIV-virus-like-particle (HLP), is 100 times more effective than other candidate HIV cure therapeutics for people living with chronic HIV on combined antiretroviral therapy (cART). If successful in clinical trials, HLP could be used by millions of people living around the world to free them of HIV. This study was done using blood samples from people living with chronic HIV.

HLPs are dead HIV particles hosting a comprehensive set of HIV proteins that increase immune responses without infecting a person. When compared with other potential cure approaches, HLP is an affordable biotherapeutic and can be administered by intramuscular injection -- similar to the seasonal flu vaccine.

"The development of this HIV cure was ten years in the making but with strong support from our collaborators in the U.S., Canada and Uganda, we have observed a striking ability of HLP to drive out the last remnants of HIV-1, which we hope will provide an affordable cure for all," said Arts, who is a Canada Research Chair in HIV Pathogenesis and Viral Control. "To live HIV-free is a goal for the 39 million infected. It is also the priority of the UN and WHO to end the HIV pandemic by 2030."

HIV is a retrovirus that attacks the body's immune system and if left untreated, can lead to acquired immunodeficiency syndrome (AIDS). The virus weakens a person's immune system by destroying CD4-T white blood cells, which are tasked with helping the immune system fight infections. Approximately 95 per cent of people living with HIV have chronic HIV -- where the virus is slowly causing a slow destruction of the patients' immune systems when they initiated lifelong cART.

While cART is effective at treating HIV, it has been unable to completely eliminate the virus from the body. This is because of the virus' ability to create a "latent reservoir" -- where it hides dormant inside of cells, safe from detection. Using blood samples from 32 participants living with chronic HIV from the U.S., Uganda and Canada, who were on stable cART for a median of approximately 13 years, researchers found that HLP was able to specifically target just the immune cells containing latent HIV reservoir and purge these cells of their HIV, a critical step towards an HIV-1 cure. An HIV cure is typically described as therapy and approach that eliminates all HIV without the need of continuous antiretroviral therapy.

"Over time, the virus grows more diverse within a single individual that is not on treatment which makes it more difficult to target," said co-lead author Ryan Ho, master's student in the department of microbiology and immunology. "This formulation we've crafted covers the theoretical diversity so it can reach the HIV-1 in all those people living with HIV."

Minh Ha Ngo, lead author and postdoctoral scholar in the department of microbiology and immunology, says one concern expressed among people living with HIV for years is that continued use of cART could lead to the virus becoming unreachable and unable to be eliminated. The results of this study, by contrast, demonstrate that combining HLP with cART is still able to trigger the latent reservoir, even in chronic cases. If these dormant latent reservoirs can be awakened, then they can be eliminated from the body.

"Owing to its high mutation rate, HIV exhibits remarkable genetic diversity, resulting in different viral subtypes; some of which predominate in particular regions of the globe," said Mann. "We were excited to see preliminary evidence that our HLP cure therapy reverses latency irrespective of the subtype of the individual's infection. Whilst this needs to be explored further, it hints at the global applicability of our approach."

In the future, researchers plan to test HLP on a larger representative HIV cohort with subtype C infections, which includes people living in South Africa, Ethiopia, Vietnam and India. This would help determine if the treatment strategy is effective for most people living with acute and chronic HIV.

Current studies involve confirming a lack of toxicity in preparation for human clinical trials.

These studies will be made possible with the advanced Pathogen Research Centre at Schulich Medicine & Dentistry. This study was conducted in collaboration with University of Bristol, University of Toronto, Case Western Reserve University, Rakai Health Sciences Program, Johns Hopkins University School of Medicine and the U.S. National Institutes of Health.

The study was funded by the American Foundation for AIDS Research, and by the Canadian Institutes of Health Research, U.S. National Institute of Allergy and Infectious Diseases; part of the National Institutes of Health, and the Canada Research Chairs Program.

• HIV and AIDS
• Infectious Diseases
• Sexual Health
• Diseases and Conditions
• Chronic Illness
• Immune System
• Antiretroviral drug
• Ionizing radiation

Story Source:

Materials provided by University of Western Ontario . Original written by Cynthia Fazio. Note: Content may be edited for style and length.

Journal Reference :

• Minh Ha Ngo, Joshua Pankrac, Ryan C. Y. Ho, Emmanuel Ndashimye, Rahul Pawa, Renata Ceccacci, Tsigereda Biru, Abayomi S. Olabode, Katja Klein, Yue Li, Colin Kovacs, Robert Assad, Jeffrey M. Jacobson, David H. Canaday, Stephen Tomusange, Samiri Jamiru, Aggrey Anok, Taddeo Kityamuweesi, Paul Buule, Ronald M. Galiwango, Steven J. Reynolds, Thomas C. Quinn, Andrew D. Redd, Jessica L. Prodger, Jamie F. S. Mann, Eric J. Arts. Effective and targeted latency reversal in CD4 + T cells from individuals on long term combined antiretroviral therapy initiated during chronic HIV-1 infection . Emerging Microbes & Infections , 2024; 13 (1) DOI: 10.1080/22221751.2024.2327371

Cite This Page :

Explore More

• What Controls Sun's Differential Rotation?
• Robot, Can You Say 'Cheese'?
• Researchers Turn Back the Clock On Cancer Cells
• Making Long-Term Memories: Nerve-Cell Damage
• A Solar Cell You Can Bend and Soak in Water
• Risk Factors for Faster Brain Aging
• Deep Space Objects Can Become 'Ice Bombs'
• Want to Feel Young? Protect Your Sleep
• Century-Old Powdered Milk in Antarctica
• New Artificial Reef Stands Up to Storms

Trending Topics

Strange & offbeat.

Scientists discover potential HIV cure that eliminates disease from cells

By Isobel Williams via SWNS

HIV could be history, as scientists have discovered a potential cure that eliminates the disease from infected cells.

At present the condition can be treated and symptoms kept in check but not actually cured.

A new study has unveiled a future cure for HIV which uses molecular scissors to “cut out” HIV DNA from infected cells.

To cut out this virus, the team used CRISPR-Cas gene editing technology— a groundbreaking method that allows for precise alterations to the genomes of living organisms.

This revolutionary technique, which brought its inventors, Jennifer Doudna and Emmanuelle Charpentier, the Nobel Prize in Chemistry in 2020, enables scientists to accurately target and modify specific segments of DNA.

One of the significant challenges in HIV treatment is the virus's ability to integrate its genome into the host's DNA, making it extremely difficult to eliminate.

The authors explain that the CRISPR-Cas genome editing tool provides a new means to target HIV DNA, which may be more effective than the antiviral drugs in circulation.

In this research, which is to be presented early ahead of this year’s European Congress of Clinical Microbiology and Infectious Diseases , the authors used CRISPR-Cas and two guide RNAs against “conserved” HIV sequences.

This means that they focused on parts of the virus genome that stay the same across all known HIV strains and achieved a cure for HIV-infected T cells.

By focusing on these conserved sections, the approach aims to provide a broad-spectrum therapy capable of combating multiple HIV variants effectively.

Their experiments showed outstanding antiviral performance, managing to completely inactivate HIV with a single guide RNA and cut out the viral DNA with two guide RNAs.

Associate professor Elena Herrera Carrillo from the University of Amsterdam AMC said: “Our aim is to develop a robust and safe combinatorial CRISPR-Cas regimen, striving for an inclusive ‘HIV cure for all’ that can inactivate diverse HIV strains across various cellular contexts.

“We have developed an efficient combinatorial CRISPR-attack on the HIV virus in various cells and the locations where it can be hidden in reservoirs, and demonstrated that therapeutics can be specifically delivered to the cells of interest.

“These findings represent a pivotal advancement towards designing a cure strategy.”

The researchers note that HIV can infect different types of cells and tissues in the body, each with its own unique environment and characteristics, so they are searching for a way to target HIV in all of these situations.

The team adds that they have a long way to go before their cure will be available to patients, but that it is a promising start.

Dr. Carrillo concluded: “We hope to achieve the right balance between efficacy and safety of this CURE strategy. Only then can we consider clinical trials of ‘cure’ in humans to disable the HIV reservoir.

“While these preliminary findings are very encouraging, it is premature to declare that there is a functional HIV cure on the horizon.”

The post Scientists discover potential HIV cure that eliminates disease from cells appeared first on Talker .

• Canada's Population
• Baltimore Bridge Collapse

• Local Change location
• Entertainment
• Perspectives

TV Programs

• Global National
• The Morning Show
• Video Centre
• More…

Radio - 980 CFPL

• Email alerts
• Breaking News Alerts from Global News
• License Content
• New Brunswick
• Peterborough

Close Local

Your local region.

• All event types

Quick Search

Trending now.

Add Global News to Home Screen Close

Instructions:

• Press the share icon on your browser
• Select Add to Home Screen

Comments Close comments menu

Want to discuss? Please read our Commenting Policy first.

Possible HIV cure 1 step closer to human trials: Ontario researchers

If you get Global News from Instagram or Facebook - that will be changing. Find out how you can still connect with us .

A new international study led by Ontario researchers is showing promise in potentially curing HIV . If it makes it through human clinical trials, it has the potential to cure millions of people worldwide, researchers say.

Approximately 95 per cent of people with HIV have it chronically, which Ryan Ho, a master’s student at Western University in London, Ont., and co-first author of the research, said can be defined as having the virus untreated for around one year. Ultimately, this causes a slow destruction of the patient’s immune system and can lead to acquired immunodeficiency syndrome (AIDS).

Worldwide, 39 million people are infected with HIV, 30 million of whom are on a cocktail of drug treatments. There are side effects and problems with these treatments, mainly that individuals need to be on them for life.

“There’s this small amount of HIV that hides itself in their body, and when you take off the drugs that virus can rebound,” says Eric Arts, professor at the Schulich School of Medicine and Dentistry at Western University and Canada Research Chair. “There’s been this goal in the HIV research field for years now to try and find something that will tickle those last few cells that have HIV to release the virus so it can be killed.”

In this new study, led out of the Schulich School of Medicine and Dentistry, their therapy has shown the ability to drive out the last remnants of HIV in blood samples of those with the virus.

“We acquired blood samples and applied our HIV virus-like particle, or HLP for short,” Ho says. “One other thing we’re looking for is if our HLP, after we apply it to the immune cells, can we detect the HIV virus releasing from these immune cells by measuring the DNA output? That’s something we were able to show.”

The first indication that this was an effective treatment was its previous success on blood samples of people who received treatment very early in their infection, but less than one per cent of the 30 million people currently in treatment began it within three months of infection.

The researchers then recruited about 50 people living with chronic HIV who had been on the current standard treatment for a significant amount of time and obtained blood samples. The researchers’ HLP treatment was used on the blood samples very similarly to how it would be given as an injection to patients, and they discovered it was a highly effective way to drive out and kill the remaining amount of virus in their blood.

“It’s very targeted, and we found out that it’s about 100-fold more effective than anything that has been tested before,” Arts says. “We could not see virus anymore that would be present that might cause them problems in the future.”

The next step is to ensure that the treatment is safe enough to move on to human clinical trials.

• ‘Running into roadblocks’: Canadian family fights to get care for daughter with epilepsy
• ‘The craving is just not there’: How Ozempic is affecting snacking culture
• Remote work and how it’s shaping where people are now buying homes in Ontario
• Ottawa signs $3.7B health deal with Quebec, final province to sign onto health accord

Ho says one of the most direct takeaways from the research is the ability to reawaken the latent HIV that hides in the immune cells of people who have been adhering to other treatment for many years.

“Us being able to acquire blood samples from people who had been taking treatment consistently for over a decade for a couple of them, and still reawakened this virus, it’s a hopeful takeaway,” Ho says.

The study was not without limitations, however. Researchers were unable to test its effectiveness in those with the C subtype of HIV, which is predominantly found in Asian continents, some of Europe and the Middle East. But subtype C is the largest proportion of the virus that is circulating.

“Targeting C and ensuring that the HLP is effective would be really representative to the existing world’s infection state,” Ho says. “Our project is an international collaboration, but those are predominantly in Uganda, in the United Kingdom, in Cleveland, and somewhere around Maryland, Baltimore, and Toronto, Ont. That’s just due to the collaborations that we have with other professors and other doctors.”

Ho says this logistical limitation is something the researchers plan to address moving forward, as it is simply an access limitation and can be corrected after various approval steps are completed.

“You can’t just acquire people’s blood,” Ho says. “There’s ethics, red tape to cross, consent forms to sign. But this (study) opens the door for that a lot easier.”

For Ho, the preventive approach on the other side of this project is equally important. Bringing attention to, promoting awareness of and preventing HIV acquisition by promoting safe sex and harm reduction are another key focus in ending the epidemic.

“One thing that I’ve gotten involved with in London is the Regional HIV/AIDS Connection where we focus on harm reduction kits,” Ho says. “People will use their substances, but we only we hope that they don’t also acquire seven different viruses by using their substances.”

David Cummings, manager of community relations at the Regional HIV/AIDS Connection, says this development is nothing short of groundbreaking. If successful in clinical trials, Cummings celebrates the significance of the research and that the therapy could offer millions of people living with HIV a cure.

“Today’s treatment options already allow people living with HIV to lead long, healthy lives,” Cummings says. “This progress represents yet another monumental leap forward in our collective response to HIV/AIDS.”

Sponsored content

Report an error, subscribe here.